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Abstract

MOLECULAR MODELING STUDIES OF HEPARIN AND HEPARIN MIMETICS
BINDING TO COAGULATION PROTEINS
By Chandravel Krishnasamy, PhD
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2009
Director: Dr. Umesh R. Desai
Professor, Department of Medicinal Chemistry

Heparin, a glycosaminoglycan (GAG), is a complex biopolymer of varying chain
length and consisting of uronic acid and glucosamine residues, which are sulfated at
various positions. The interaction of heparin with antithrombin is the basis for
anticoagulation therapy. Heparin accelerates the antithrombin mediated inhibition of factor
Xa and thrombin by a conformational activation mechansism and bridging mechanism,
respectively. The sequence specific pentasaccharide DEFGH in full length heparin is the
most important fragment for high affinity and activation of antithrombin, without which
the heparin is incapable of binding to antithrombin. Although heparin is a commonly used
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anticoagulant, it suffers from serious side effects including bleeding complications,
heparin-induced thrombocytopenia, and intra- and inter-patient dose response variability.
Desai and co-workers have shown that it is possible to replace the GAG skeleton
by small, non-saccharide sulfated molecules as antithrombin activators. However, the
designed molecules were found to be weak activators of antithrombin due to their binding
to the extended heparin-binding site (EHBS), instead of the pentasaccharide-binding site
(PBS), of antithrombin.
To design better non-saccharide antithrombin activators, a virtual screening-based
approach was employed. Combinatorial virtual screening of 24576 molecules based on
tetrahydroisoquinoline core scaffold resulted in 92 hits that were predicted to bind
preferentially in the PBS of activated antithrombin with good affinity. The work resulted in
a predicted pharmacophore consisting of a 5,6-disulfated bicyclic tetrahydroisoquinoline
and a 2′,5′-disulfated unicyclic phenyl ring connected by a 4- to 5-carbon linker. The work
has led to several hypotheses, which are being tested in the laboratory through synthesis
and biochemical evaluation.
To understand the mechanism of heparin binding to thrombin in greater detail,
structural biology and molecular modeling approaches were used. More specifically, the
nature of the heparin binding to thrombin was studied with a special focus on
understanding the specificity of recognition. Comparative analysis was performed with
heparin–antithrombin interaction to assess similarities and differences between the two
heparin binding systems. In antithrombin, three important amino acids are involved in
heparin pentasaccharide binding, while in thrombin, at least seven basic amino acids are
xii

predicted to be involved. For biological systems, one would expect greater specificity with
more interacting points. However, the heparin–thrombin system interestingly displays a
lack of specificity. The molecular basis for this lack of specificity is not clear.
A study of antithrombin and thrombin crystal structures with regard to surface
exposure, flexibility, and geometry of basic amino acids present in the respective heparin
binding site provides the basis for the specificity of recognition (or lack thereof) in the two
systems. Interestingly, analysis of thrombin exosite-II showed that Arg101, Arg165 and
Arg233 are spatially conserved and form a local asymmetric center. Using in-silico
docking techniques, selected tetrasaccharide sequences were found to specifically
recognize this triad of amino acids indicating the possibility of specific recognition of
thrombin. This hypothesis led to the design of a putative lead sequence that is 50% smaller
in size and contains 62.5% fewer charges in comparison to the literature reported known
exosite II sequence. The design of novel putative ‘specific’ exosite II sequence challenges
the idea that the thrombin–heparin interaction is completely non-specific and gives rise to
novel opportunities of designing specific thrombin exosite-II ligands.

xiii

CHAPTER 1
INTRODUCTION

Drug design is the process of finding drugs for a particular disease or condition by
design, unlike the traditional trial-and-error method or serendipitous discovery. Design, by
definition, implies that there is a strategy involved to confront a problem. If design
involves rational thoughts and reasoning, then such a process is termed rational drug
design. Rational drug design that utilizes the known three-dimensional geometry of a
biological target is known as structure-based drug design (SBDD).1 In contrast, drug
design directed only by the known geometry of a potent ligand is referred to as ligandbased drug design (LBDD).1,2
The fundamental principle that forms the basis for structure-based design is
structural and chemical complementarity between the target and its ligand. The threedimensional geometry of a target is used either to design completely new ligands or to
choose existing ligands by screening collections of compounds. Identifying completely
new chemical classes of molecules that are chemically distinct from previously
characterized leads for a biological target is termed de novo drug design.1 However,
modifying a ligand to improve its physiochemical, pharmacological and drug-like
properties is known as lead optimization.
1

Development of a drug that is potent, efficient, and orally bioavailable, and has
minimal or no side effect is a lengthy process involving major investments including an
enormous amount of time (usually about 10 to 12 years) and billions of dollars. Any effort
or tools that reduce the time and money spent in drug discovery can significantly influence
the way drugs are discovered, and is considered an utmost need for pharmaceutical
interests and for the benefit of suffering patients.
1.1.

Computer-Aided Drug Design (CADD)1
The important role of CADD in the drug discovery process is to accelerate the

identification of new lead compounds and lead optimization for a biological target/process
(Figure 1). The pipeline of drug discovery from idea to market consists of the following
general basic steps: a) disease selection, b) target selection, c) lead compound
identification, d) lead optimization and e) preclinical and clinical studies.
In practice, these steps are repeated and revisited at several stages based on the
results in each step. The compounds for testing can be obtained from natural sources such
as plants, animals, microorganisms and by chemical synthesis. Not all compounds become
lead compounds with optimal properties that can go on to become a drug candidate, and
many fail owing to the absence of activity, poor pharmacokinetic disposition, unacceptable
toxicity, insufficient efficiency, or even complexity of synthesis.
Extensive genome decoding of various organisms, including man, proteomic
investigations, discoveries of molecular mechanisms of many diseases, and advances in
protein chemistry have led to a dramatic increase in the number of new potential targets.
2

The advancement in these areas of science and the results they produce could be exploited
to find new lead compounds by employing computer-based theoretical and experimental
approaches.

Figure 1. Pathways of computer-aided drug design (simplified). LBDD: Ligand-Based
Drug Design, SBDD: Structure-Based Drug Design, QSAR: Quantitative StructureActivity Relationship. Adapted from Veselovsky, A. V.; Ivanov, A. S. Strategy of
computer-aided drug design. Current Drug Targets – Infectious Disorders 2003, 3, 33-40.
3

1.2.

Hardware and Software Requirements
Modeling of the interactions of macromolecules with ligands requires various

methods of calculations and structural visualization. Such studies often require
multiprocessor computer systems under UNIX management.

Two widely used

commercial software packages for CADD are SYBYL (http://www.tripos.com) and Insight
II/Discovery Studio (http://www.accelrys/insight). These software packages have many
modules that are designed to facilitate various aspects of the drug design process. Many
other freeware and shareware molecular modeling programs are also available for
molecular modeling purposes. It is crucial to have access to databases with structures of
macromolecules and small compounds. The structures of proteins are assembled in Protein
Data Bank (PDB; http://www.rcsb.org/pdb) as PDB files from which protein coordinates
can be downloaded. Small molecules are available in the Cambridge Structural Database
(CSD; http://www.ccdc.cam.ac.uk/prods/csd/csd.html). Primary sequence data is provided
by

the

National

Center

for

Biotechnology

Information

(NCBI;

http://www.ncbi.nlm.nih.gov), and the European Molecular Biology Laboratory (EMBL;
http://www.ebi.ac.uk/embl/)

and

the

Swiss

Institute

of

Bioinformatics

(http://www.expasy.org). Many other databases of low-molecular weight compounds are
also available, but databases with commercially available compounds are preferable for
practice, because these compounds can be quickly acquired for experimental testing
(ZINC; http://zinc.docking.org).

4

1.3.

Ligand-Based Drug Design
Ligand-based drug design is applied when the three-dimensional structure of the

macromolecular target is unknown. These methods are based on analysis of sets of ligands
with known biological activity. They include the design of pharmacophore models,2
analysis of quantitative structure-activity relationships (“classic” QSAR)3 and its relative
3D-QSAR (which takes into account spatial structure of compounds),4 quantitative
structure-property relationships (QSPR),5 among others. Methods of LBDD can be used
for lead compound discovery and lead optimization of previously known ligands.
Pharmacophore models consist of a set of points in space with the specific
physiochemical properties and corresponding distances between them that define the
elements necessary for the binding of a given group of ligands with a target.
Pharmacophore elements include positively and negatively charged atoms, cyclic groups,
aromatic rings, and hydrogen bond donor or acceptor atoms. Such a model is designed by
alignment of a set of known ligands to reveal commonly-shared features of different
molecules in one molecular space area.
1.3.1. Classic QSAR
Quantitative structure-activity relationships are mathematical relationships linking
the chemical structure and pharmacological activity in a quantitative manner for a series of
compounds. It is generally accepted that Crum-Brown and Fraser were the first to link
physiological action θ and “chemical constitution” C using the expression shown below.6
5

Eq. (1)
Meyer and Overton correlated biological activity with oil/water partition
coefficients of a series of narcotic substances, which added credence to the above
equation.7,8 One of the most widely utilized, successful empirical approaches using
descriptors is Linear Free Energy Relationships (LFER) as embodied in the early work of
Burkhard, the equations of Louis Hammett and the contributions of Corwin Hansch.9-12
Corwin Hansch considered drug action to be a result of two independent processes:
i) Transport of the drug from the site of application to the site of action and ii) Noncovalent interactions of the drug with its binding site receptor. Since neither very polar nor
very lipophilic compounds have a good chance to permeate several lipid and aqueous
phases, he formulated a nonlinear lipophilicity relationship for the transport. Later,
lipophilicity terms and electronic parameters, molar refractivity and steric terms were
combined in a linear free energy related model to describe the ligand-receptor interaction.
From the inception of QSAR, various descriptors have been developed. The
following are important categories of descriptors that have been combined to generate the
linear and nonlinear equations that are common to QSAR.
Electronic Descriptors: Hammett’s electronic descriptor σ is described by the following
equation:

σ

log

KX

Eq. (2)

KH

6

KX and KH represent the ionization constants in water at 25 °C of substituted and
unsubstituted benzoic acids, respectively. Sigma (σ) is defined as a substituent constant
such that positive values of σ represent electron-withdrawing substituents and negative
values of σ pertain to electron-releasing substituents. It was subsequently modified as:

ρσ

log

KX

KH

Eq. (3)

The proportionality constant rho (ρ) is defined as a reaction constant and is specific
for each reaction under its unique constraints. Thus, ρ is a measure of the susceptibility of a
given reaction to the electronic effects of substituents. Numerous other Hammett-based
electronic parameters are available.
Hydrophobicity: Hydrophobicity may be defined as the tendency of organic molecules to
shy away from water and partition into a less polar phase, which constitutes their own
bulk.13 The classical model of hydrophobic interactions was delineated by Kauzman to
assess van der Waals attractions between the nonpolar parts of two molecules immersed in
water.14 The "squeezing out" of water molecules in the vicinity of the mutually bound
apolar surfaces provides the driving force for hydrophobic interactions. Thus, the gain in
entropy is primarily governed by the repulsion of hydrophobic solutes from solvent water
and the limited but critical capacity of water to maintain its network of hydrogen bonds.15
A hydrophobe immersed in water decreases the entropy of the water by forcing the water
molecules to form a ‘clathrate’ cage structure around the hydrophobic portion. The
decrease in entropy is thermodynamically unfavorable.
7

Steric Descriptors: Steric descriptors represent the bulkiness of molecules. The first steric
effect in physical organic chemistry to be numerically defined was Taft's ES parameter.16 It
was defined as the ratio of the log of acidic hydrolysis of aliphatic esters of the type
RCOOR' and CH3COOR'.

log

Eq. (4)

Other often-utilized steric descriptors in SAR studies include Charton's steric
parameter,17,18 Hancock's steric parameter,19 molar refractivity,20 Verloop's STERIMOL
parameters21 and Hopfinger's molecular shape analysis.22
Hydrogen Bonding Descriptors: The importance of hydrogen bonding, a fundamental
chemical property in biological systems, is highlighted by its critical role in defining the
structure of biomacromolecules like proteins and nucleic acids. Hydrogen bonding ability
is classified into hydrogen bond donor and acceptor capacities. The importance of
hydrogen bonding is unequivocally recognized in ligand-receptor interactions. Most often,
the hydrogen bonding capacity of a molecule is encoded as the number of hydrogen bond
donors, acceptors or donatable hydrogens.
Dipole Moments: Dipole moments, μ, have been successfully used to correlate biological
activity where whole-molecule parameters are critical. A large number of group dipole
moments for aromatic and aliphatic substituents have been assessed by Lien et al.23,24
Quantum Chemical Indices: Use of quantum chemical descriptors is constantly
increasing because of the developments in high-speed computing, as well as the accuracy
8

and precision of computed values.25 Direct derivation of electronic descriptors can be
obtained from the molecular wave function. The most common approach utilized for
solution of the electronic Schrödinger equation is the Hartree-Fock self consistent field
(SCF) method.26 Thus, each electron is assumed to move in the average field of all the
other electrons. Two different approaches are used to solve the molecular Schrödinger
equations: ab initio and semi-empirical.
ab initio calculations include all electrons and all one- and two-electron integrals.
Computational time is proportional to a high exponential of the number of electrons in the
molecule (N4 or N5). Thus ab initio calculations are limited by the types of atoms and size
of molecules.27
In semi-empirical methods, only valence electrons are explicitly included; some
integrals are neglected and others are approximated.28 CNDO (neglect of diatomic and
single atom atomic orbital overlap), MNDO, AM1 and PM3 (neglect of diatomic overlap
only) are commonly used to methods calculate molecular descriptors such as atomic
charges

(qX),

molecular

orbital

energies

(EHOMO,

ELUMO,

ELUMO–EHOMO),

superdelocalizabilities (s), molecular polarizability (α), dipole moments (μ) and energies
(ET). For a detailed description of all parameters, see reference 25.
Topological Indices: In general, topology refers to the way in which atoms are connected
to each other in a molecule thus representing the shape of the molecule. The best-known
topological parameters are the molecular connectivity indices which are strictly based on
molecular structure.
9

1.3.2. 3D-QSAR
In 3D-QSAR, the 3D structure of the compounds is considered instead of only 2D
structure. 3D-QSAR has some advantages over classical 2D-QSAR. For example, more
heterogeneous sets of compounds can be included than in classic QSAR. Molecular fields
are calculated instead of substituent constants, and contour maps can be prepared to show
the effect of certain properties in specific regions. CoMFA (Comparative Molecular Field
Analysis)4 and CoMSIA (Comparative Molecular Similarity Index Analysis)3 are wellknown examples of 3D-QSAR.
The ligand-based drug design methodologies like classic QSAR and 3D-QSAR
have been used for its predictive power more often than design purposes, in part due to the
difficulties involved in translating the descriptor information into meaningful structural
interpretation. In recent years, SBDD has been employed more extensively than LBDD
since the former provides detailed and easily-interpretable information about the target of
interest. However, LBDD can be employed to model ADME-Tox (Absorption,
Distribution, Metabolism, Excretion and Toxicity) properties.
1.4.

Molecular Docking and Scoring
The docking process can be defined as the search for the correct binding geometry

of the ligand (binding mode or pose) in a target binding site. In general, the docking
process consists of two interrelated components namely; identification of the binding mode
and the prediction of binding affinity.29
10

The first part of the docking process is the sampling of the ligand (and sometimes
the receptor) conformational space and placement of the ligand into the receptor binding
site. The second part is strictly a ranking process of the different docked solutions (poses)
using the scoring function, which in turn may be correlated to binding affinity.
The docking process involves the translation of theoretical model of the enzyme
inhibition or ligand recognition into a computational model. For example, for an enzyme E
and inhibitor I, docking aims at predicting the correct structure of the complex [E+I] = [EI]
under equilibrium conditions.
I

E
KA

KI

EI
EI

Eq. (5)
Eq. (6)

E I

∆

Eq. (7)

Calculation of the free energy of binding (ΔG) is related to binding affinity KA by
equations 6 and 7. Although prediction of the correct binding geometry of the [E+I]
complex does not require information about KA, prediction of biological activity requires
this information. Therefore, docking process must consider the following important
factors: steric, electrostatic, hydrogen bonding, inhibitor strain (if flexible) and enzyme
strain. In addition, when considering the equilibrium shown in Equation 5, the following
factors are also important: desolvation, rotational entropy and translational entropy.

11

1.4.1. Molecular Docking Algorithms
Protein-ligand docking is a geometric search process. The output from the docking
algorithm includes a list of protein-ligand complexes rank-ordered by a given scoring
function.30 Several docking algorithms have been developed that place rigid or flexible
ligands in mostly rigid-but recently also somewhat flexible protein binding sites (e.g.,
DOCK,31-34 MOE-Dock,35AutoDock,36 FlexX,37-39 Hammerhead,40 GOLD,41 FLOG,42
Glide,43 PRO_LEADS44). Some algorithms allow partial protein flexibility. Docking
algorithms are complemented by scoring functions that are designed to identify the correct
binding mode. Various functions have been developed to measure the protein-ligand
binding affinity in the docking algorithms. Since many of the functions are not strictly
related to binding free energies, functions designed to rank different protein-ligand
complexes are referred to as scoring functions.45-48
A. Rigid Docking
In rigid docking, the docking problem is simplified by neglecting the
conformational degrees of freedom of the ligand molecule. The algorithms based on this
approximation can be applied to docking of small or rigid molecules, molecule fragments
or conformational ensembles of molecules.
a. Clique Search-Based Approaches
The docking of two rigid molecules can be implied as a problem of matching
characteristic features of the molecules in space.49 A distance compatibility graph is used
12

to search for matching features. The algorithm for rigid-body docking in the DOCK
program is based on the idea of searching for distance-compatible matches. Since its first
introduction in 1982, the DOCK software has been extended in several directions.
Furthermore, several scoring functions are now applied in combination with the DOCK
algorithm.50-54 Algorithms based on clique-search based approaches also include LUDI,54,55
CLIX56 and ADAM57 but differ in the features used for matching and the way in which
they are represented.
b. Geometric Hashing30,58
Hashing is a computer science technique which allows fast access to data. The
geometric hashing algorithm has two phases: the preprocessing phase, in which the
geometric hash table is constructed from a single ligand or a set of ligands to be docked
and the features are stored. In the recognition phase, the protein features are used to vote
for hash entries of the ligand. A vote means that there is a protein feature that matches a
ligand feature. Geometric hashing is a time-efficient method. Pose clustering is another
approach used in molecular docking, which is primarily based on pattern recognition but
also uses the hashing scheme to match features.59,60
B. Flexible Ligand Docking
Rigid docking is very limited in that the conformation of the bound ligand must be
known before the docking process begins in order to obtain accurate results. Since most
drug-like molecules have at least a few rotatable bonds or even flexible ring systems, it is
13

important to incorporate ligand flexibility into any generally applicable docking algorithm.
Algorithms that treat ligand flexibility can be classified into essentially three categories: a)
systematic methods (incremental construction, conformational search, databases); b)
random or stochastic methods (Monte Carlo, genetic algorithms, tabu search) and c)
simulation methods (molecular dynamics, energy minimization).
I)

Systematic methods
a. Conformational Search
In principle, every conformer of a set of flexible ligands could be evaluated with

rigid-body docking algorithms. However, as the size of the conformational ensemble
increases computing time also increases exponentially. Thus a balance between computing
time and the desire to cover all of conformational space is required. The Flexibase and
FLOG docking algorithms are based on conformation ensembles and use libraries of pregenerated conformations.61-63
b. Fragmentation
Fragmentation is one of the most popular approaches for handling ligand
flexibility. The ligand is divided into smaller fragments which can be treated as
conformationally rigid or by a small conformational ensemble. There are two ways of
handling fragments in the active site, namely “place-and-join” and “incremental
construction”.

14

In place-and-join strategy64-67 all (or a subset of) fragments are placed in the
receptor site independently and reconnected in favorable orientations until they constitute a
complete ligand.
Incremental construction is the preferred fragmental molecular docking approach,
in which a fragment is first placed in the receptor site and then the remaining fragments are
added to the orientations of the first one. The first incremental construction based docking
algorithm was developed by Leach and Kuntz68 for the DOCK program. FlexX is a fullyautomated incremental construction algorithm-based molecular docking approach
developed for virtual screening.69-72 Glide43 and Hammerhead40 are two other approaches
that are based on incremental construction.
II)

Random or Stochastic Methods
a. Genetic Algorithms
The genetic algorithm73 is a general purpose optimization method that adapts the

principles of biological competition and population dynamics. Application of the genetic
algorithm in molecular docking includes a linear representation of a ligand and receptor
conformation called chromosomes and a fitness function to decide which individuals
survive and produce the offspring. The chromosomes that correspond to the best
intermediate solutions are subjected to crossover and mutation operations analogous to
gene recombination and mutation to produce the next generation of ligand/receptor
conformations.
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For docking applications, the genetic algorithm solution is an ensemble of possible
ligand conformations. Jones et al. developed one of the first genetic algorithms for
molecular docking and their ideas are implemented in the GOLD docking program.74,75
b. Monte Carlo Algorithms
In Monte Carlo (MC) simulation, the local movements of the atoms are performed
randomly. The two major components of the MC algorithm are the description of the
degrees of freedom and the energy evaluation. The degrees of freedom should be described
such that high-energy states are avoided. The energy evaluation is the most timeconsuming part of the process and must be made as efficient as possible. Often energy
potentials are precalculated on a grid to speed up this step. QXP, ICM, and PRODOCK are
examples for MC-based docking algorithms.76-78
c. Tabu Search
Tabu search starts with an initial random structure and new structures are created
by random moves. During the optimization iterations, a list (the tabu list) is maintained
containing the best and most recently visited configurations. Moves resulting in
configurations close to one in the tabu list are rejected except if they are better than the
best-scoring one. This technique improves the sampling properties by avoiding revisitation
of previously sampled configurations. Tabu search is the underlying method of docking in
PRO_LEADS.79
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III)

Simulation methods
Simulation approaches begin their calculation with a starting conformation and

move locally to conformation with lower energy instead of trying to list the population of a
discrete low-energy subspace of the problem. Simulated annealing and molecular
dynamics are two important simulation techniques for solving the docking problem.
a. Simulated Annealing80-83
The simulation process starts with an initial configuration A of a ligand in an active
site with energy E(A) or score value. This initial configuration is scored. Then, it generates
a new configuration B with energy E(B) and also scored. If a new solution scores better
than the previous one, it is immediately accepted. These steps are repeated until the desired
number of configurations is obtained. The AutoDock program for protein-ligand docking
developed by Goodsell et al. is based on the simulated annealing technique.80
b. Molecular Dynamics
Molecular Dynamics simulations can in principle be used to solve molecular
docking problems.84-89 However, the limitation with this methodology is that it is quite
time consuming. It follows a path from a starting orientation to low-energy configurations.
In addition, several simulations with different starting orientations must be performed to
get a statistically significant model. Though this method is not very popular for virtual
screening, it is a valuable method for analyzing small sets of ligands.
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1.4.2. Molecular Docking: Scoring Functions
Scoring functions in molecular docking process have a twofold function: to direct
the docking and to predict the binding affinity of the final poses. The evaluation and
ranking of predicted ligand conformations (pose) is a vital part of the structure-based
virtual screening.
Binding free energy is a collective term of many factors and can be written as:
∆
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∆
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is interaction energy of the protein−ligand, ∆

the entropy for protein−ligand interaction and ∆

is solvation
°

is change in

is conformational change in

protein−ligand complex.90
Accurate and reliable prediction of binding free energy by computational methods
is a very challenging task. For example, the entropy, a phenomenon that is very influential
in the physiological condition where the protein-ligand interaction takes place, can only be
crudely estimated. Another problem is that the fast estimation of binding free energy
implemented in docking programs makes various assumptions and simplifications
contributing to inaccuracy in the result. We will briefly discuss the different scoring
functions here in this chapter.

18

Essentially, four types or classes of scoring functions are currently applied: force
field-based, semi-empirical, empirical and knowledge-based scoring functions.
Scoring functions derived from a force field use non-bonded interaction terms to
calculate the score, sometimes in combination with solvation terms. Semi-empirical
approaches are those in which molecular mechanics terms are supplemented by additional
parameters or terms that are empirically derived from observation. Empirical scoring
functions employ multivariate regression methods to fit coefficients of physically
motivated structural functions by using a training set of protein-ligand complexes with
measured binding constants. Knowledge-based scoring use statistical atom pair potentials
derived from structural databases as the score.
A. Force Field Scoring
Standard force field scoring functions were originally based on the idea of using
only enthalpic gas-phase contributions to estimate the binding free energy. The main
advantage of force field scoring is that when used on a precomputed grid, it is fast and
transferable. The disadvantage is that force field scores evaluate only parts of the relevant
energies, namely, potential energies and ignoring some fundamental contributions such as
hydrophobic interactions, solvation, and entropic effects. Though there are many force
fields used, the well-known and widely-applied molecular mechanics (MM) force fields
include AMBER,91,92 CHARMM,93 TRIPOS,94 MM2,95 MM396 and MM4.97
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Energy calculations performed by these methods are essentially the sum of
electrostatic and van der Waals potentials, plus internal (i.e., intramolecular) distance,
angle and torsion contributions:90

2

∑

1

cos

Eq. (9)

Where, Kr is spring constant, r is the distance between two atoms, req is the
equilibrium bond length, Ke is angle bending force constant, θ is bond angle and θeq is
equilibrium bond angle, Vn is the torsional barrier, n is periodicity, φ is the torsion angle, γ
is phase shift (offset), Aij is repulsive force constant, Bij is attractive force constant, Rij is
distance between atoms i and j, qi is charge (partial charge) of atom i, qj is charge (partial
charge) of atom j and ε is dielectric constant.
Most force field scoring functions only consider a single protein conformation,
which makes it possible to omit the calculation of internal protein energy, which greatly
simplifies scoring.
B. Semi-empirical Scoring Functions
Semi-empirical approaches imply the use of empirical or empirically-calibrated
energetic terms for calculating interactions not commonly computed by molecular
mechanics. Although this strategy allows the inclusion of contributions for fundamental
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biological interactions, e.g., hydrogen bonding or solvent effects, semi-empirical models
partially lose the universal applicability typical of MM force fields. ICM, GOLD,
AutoDock, SDOCK, are some of the docking algorithms that includes semi-empirical
scoring functions.
C. Empirical Scoring Functions
Empirical scoring functions estimate the binding free energy by summing
interaction terms derived from weighted structural parameters, as first proposed by Böhm.
The design of empirical scoring functions is based on the idea that binding energies can be
approximated by a sum of individual uncorrelated terms. The weights are obtained by
fitting the scoring function to experimental binding constants of a training set of protein–
ligand complexes.
The functional forms of empirical scoring functions are often simpler than forcefield scoring function and are simple to evaluate, but they are based on approximations
similar to force field functions. The main drawback of empirical scoring functions is that it
is unclear whether they are able to predict the binding affinity of ligands structurally
different from those used in the training set.98,99
D. Knowledge-Based Scoring Functions
Knowledge-based scoring functions are designed to reproduce experimental
structures rather than binding energies. Knowledge-based scoring functions represent the
binding

affinity

as

a

sum

of

protein−ligand atom-pair interactions. Popular
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implementations of such functions include Potential of Mean Force (PMF),100-102
DrugScore103 and SMoG.104 The major advantage of knowledge-based scoring functions is
their computational simplicity, which permits screening of large compound databases.
E. Consensus Scoring
Given the fact that currently no scoring function performs consistently better than
the others for multiple targets,105 two strategies have emerged: identifying the best
performing function for each target or merge several scoring functions in a consensus
approach. Consensus scoring could reduce the number of false positives identified by
individual scoring functions. The concept of consensus scoring was first introduced by
Charifson106 based on the assumption that the combination of different functions would
overcome inherent individual weaknesses and lead to better and more general scoring
performance. A very good example for implementation of consensus scoring is XCSCORE107 which combines GOLD-like, DOCK-like, ChemScore, PMF and FlexX
scoring functions. A limitation of consensus scoring arises when terms in different scoring
functions are significantly correlated, where calculation errors are amplified rather than
balanced.
1.5.

Molecular Docking: GOLD Docking Protocol108
GOLD (Genetic Optimization for Ligand Docking) is a genetic algorithm for

docking flexible ligands into protein binding sites. GOLD was written by Gareth Jones
(University of Sheffield, UK) in DTI LINK (the Department of Trade and Industry)
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collaboration with GlaxoWellcome and the Cambridge Crystallographic Data Centre
(CCDC).
1.5.1. Preparing the Protein Structure for Docking
Protein coordinates extracted from PDB (Protein Data Bank) files usually need to
be pre-processed prior to docking. All hydrogen atoms are added including those necessary
to define the correct ionization and tautomeric states of residues such as Asp, Glu and His.
All bond types are checked. The sequence order, name of the sequence and atoms are
correctly typed and named. Any unusual bonds such as disulphide bridges are checked to
see if they have CONECT records. If a metal ion is present, all bonds between the ion and
coordinating protein or water atoms are deleted (GOLD finds them automatically).
The corrected protein file is saved in MOL2 format. GOLD assigns atom types
from the information about element types and bond orders in the input structure file, so it is
important that these are correct.
1.5.2. Preparing the Ligands for Docking
Structure building tools are available in many modeling software packages
including SYBYL. Ligands can be drawn and energy-minimized before docking. In order
to predict correct protein−ligand binding modes for the ligand, all hydrogen atoms,
including those necessary to define the correct ionization and tautomeric states are added
and that all bond types are checked for its correctness.
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For groups which can be drawn in more than one way (i.e., have more than one
canonical form), such as nitro, carboxylate, sulfate and amidinium a special attention must
be paid in defining their atom type and bond type (Figure 2).
The starting geometry of the ligand should be reasonably low in energy, since
GOLD will not alter bond lengths or angles, or will rotate rigid bonds such as amide
linkages, double bonds and certain bonds to trigonal nitrogens. However, GOLD optimizes
the values of torsion angles around rotatable bonds. The corrected ligand is saved as a
MOL2 file.

¯

A. Standard sulfate
representation

B. Sulfate representation for GOLD docking
(SYBYL atom type o.co2)
¯

C. Standard carboxylate
representation

D. Carboxylate representation for GOLD
docking (SYBYL atom type o.co2)

Figure 2. Standard molecular representation of sulfate and carboxylate groups (A and C).
In GOLD, the bond types of all three terminal S-O and two C-O bonds are treated as
aromatic bonds and the terminal oxygens are treated equally as charged carboxylate
oxygens (B and D). This redefinition of sulfate group is important for docking purposes in
order for GOLD to correctly recognize the sulfate group. In reality, each of the terminal
oxygens are (partially) charged, not just one as shown in the standard representation (A
and C).
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The precise geometric positions of rotatable (e.g., hydroxyl and amino) hydrogen
atoms do not matter, as they are optimized during the GOLD run. GOLD deduces
hydrogen-bonding abilities from the presence or absence of donatable hydrogen atoms. For
example, the protonation state of a carboxylic acid group can be controlled by adding or
removing the ionizable hydrogen atom.

GOLD ignores assigned atom charges, both

formal and partial. It deduces whether an atom is charged by counting the bond orders of
the bonds that it forms and comparing the result with the atom’s normal valence.
Since ring conformations and the torsion angles around rigid bonds such as amide
linkages, double bonds and certain bonds to trigonal nitrogens are normally fixed at their
starting values during docking, a good practice is to perform a few cycles of molecularmechanics minimization to take the ligand close to its local potential-energy minimum.
GOLD does not alter stereochemistry. Care must be taken to ensure that the ligand
possesses the correct stereochemistry. In cases where we are not sure about the
stereochemistry or if it is undefined, alternate stereoisomers must also be generated to
make comparisons between fitness scores for dockings of different stereoisomers.
1.5.3. Ligand Flexibility: Fixing Rotatable Bonds
Although GOLD is designed to dock flexible ligands into protein binding sites, it
also can be useful to fix the geometry of part or all of the ligand e.g., in order to study the
possible binding of a pre-determined ligand geometry. This also restricts the search space,
therefore convergence may be higher. This can be used to greatly simplify the docking of
large molecules with inflexible regions (i.e., the rigid backbone hypothesis).109
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1.6.

Molecular Docking of Sulfated Molecules

1.6.1. Molecular Docking Sulfated Glycosaminoglycans (GAGs)
Glycosaminoglycans (GAGs) are complex carbohydrate biopolymers also known
as mucopolysaccharides because of their viscous lubricating properties as found in mucous
secretions. GAGs interact with a wide range of proteins and exhibit important roles in
various physiological and pathological processes such as inflammation, coagulation,
angiogenesis, cell adhesion and viral invasion by interacting with several different
proteins.110-112
Heparin and
Heparan sulfate (HS)

Chondroitin sulfate (CS)

Glucosaminoglycans

Galactosaminoglycans

Dermatan sulfate (DS)

Glycosaminoglycans (GAGs)
Sulfated GAGs

Non-sulfated GAGs

Chondroitin sulfate (CS)
Dermatan sulfate (DS)
Keratan sulfate (KS)
Heparin and
Heparan sulfate (HS)

Hyaluronic acid (HA)

Figure 3. A simple classification of glycosaminoglycans.
The linear, sulfated, negatively charged GAGs are built up of several different
sulfated disaccharide units.113 The repeating units are composed of alternating uronic acids
(D-glucuronic acid or L-iduronic acid) and amino sugars (D-galactosamine or D26

glucosamine). GAGs are differentiated according to the type of hexosamine, hexose or
hexuronic acid unit that they contain, as well as the geometry of the glycosidic linkage
between these units (Figure 3).
The disaccharide unit may be sulfated or unsulfated at various positions and the
ring system can exist in different conformation. GAGs also vary in the geometry of the
glycosidic linkage (α or β). As a result, there exists exquisite structural complexity in the
GAG sequences.114 At physiological pH, all carboxylic acid and sulfate groups may be
deprotonated, giving GAGs very high negative charge densities (heparin has the highest
negative charge density of any known biomolecule).115

A. IdoA2S β (1→4) GlcNS6S

B. GlcA β (1→3) GlcNAc
Figure 4. Examples of basic structural units of GAGs. A. L-iduronic acid 2-O-sulfate and
D-glucosamine 2-N-sulfate-6-O-sulfate linked together via α (1→4) glycosidic bond is a
major disaccharide unit in heparin. B. D-glucuronic acid and D-N-acetyl glucosamine,
linked together via alternating β (1→3) and β (1→4) glycosidic bonds is a repeating
disaccharide unit in hyaluronic acid.
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The structural complexity of GAGs and their roles in various physiological
processes makes their targets excellent candidates for structure/ligand-based drug design,
where recent developments in molecular modeling techniques could be applied to expedite
the understanding of this complex system (structural complexity and molecular modeling
details in Chapter 3).
Molecular modeling and docking as a tool for drug design has been successfully
used in many instances where small organic molecules modulate the actions of
macromolecules, but molecular docking of sulfated GAGs has not been explored much due
to their high negative charge density and conformational flexibility. If all possible
conformations of the GAG oligosaccharide and all rotamers of charged side chains in a
protein are to be taken into account, an accurate prediction of GAG-protein binding
becomes an extremely challenging task.
Molecular modeling techniques have been described for the successful prediction
of sulfated GAG binding sites on the surface of proteins. These methods include energy
mapping of ligand probes on the surface of proteins, molecular docking and scoring, and
molecular dynamics simulations.116,117
The prediction of the location of GAG binding sites on the surface of the proteins
have been attempted by mapping of sulfate interaction energies using GRID followed by
ligand-protein docking to predict the most favorable anchoring position for a charged
sulfate group on the surface of proteins.118 Such studies have been performed with a
number of proteins such as aFGF (acidic Fibroblast Growth Factor), bFGF (basic
Fibroblast Growth Factor), antithrombin and IL-8 (Interleukin-8).119
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Most docking studies on heparin-binding proteins have been focused on predicting
the amino acids that make up the heparin binding sites.120 Simulated annealing and genetic
algorithms have been used to dock GAGs to their putative proteins or receptors.121-126
Since heparin and related GAGs are structurally complex, the prediction of binding
modes and energies for these molecules to their biological receptors requires a sufficiently
large conformational sampling from the large search space along with an adequate scoring
function.
Lam et al. have reported molecular modeling studies to predict the binding of a
heparin hexasaccharide to the multi-component complex between bFGF and FGFR1
(Fibroblast Growth Factor Receptor-1).126 The proposed structural model of the
biologically functional dimeric bFGF-heparin complex between heparin, bFGF and
FGFR1 has a stoichiometry of 1 heparin: 2 bFGF: 2 FGFR1. This model is consistent with
the binding mechanism of FGF to its receptor, the receptor dimerization, and the reported
site-specific mutagenesis and biochemical cross-linking data.126
In another study, molecular docking predicted that long heparin fragments such as a
dodecasaccharide or a tetradecasaccharide are required for binding to the dimer of
chemokine stromal cell-derived factor 1α (SDF-1α).127
A study of the interaction between a heparin pentasaccharide and AT-III has been
carried out by Grootenhuis and van Boeckel by homology modeling and manual docking.
However, the geometry determined by them was different from the original crystal
structure.128
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The first approach of combinatorial library screening for Heparin/Heparan Sulfate
(heparin/HS) GAGs has been reported and this study demonstrates that library screening is
feasible for heparin/HS oligosaccharides, especially if a high-resolution crystal structure of
the protein is available.109 This work describes identification of high-affinity high
specificity heparin/HS sequences that bind antithrombin utilizing a combinatorial virtual
library screening approach. The approach relies on a dual-filter strategy involving affinity
and specificity filters and is based on an average heparin/HS backbone hypothesis. The
approach uses a genetic algorithm-based docking and scoring protocol (additional
information in Chapters 2 and 3).
Current docking methods aimed at predicting high-affinity GAG sequences have
certain limitations that need to be addressed. Since most docking methods based on coarse
docking generally fail to take into account any conformational changes that may occur in
the protein receptor, it is necessary to include sequences that have both 1C4 and 2SO ring
conformations for iduronic acid. Molecular dynamics simulations suggested that the chair
form (1C4) predominates at monosaccharide level of IdoA2S and the skew-boat (2SO) may
contribute from ~40% to 60% of the total IdoA2S conformational preference in the entire
polysaccharide chain depending on the heparin sequence.129-132
In addition, GAG oligosaccharides have many rotatable bonds (large number of
degrees of freedom), posing a significant challenge for the search of the correct binding
mode. An additional problem arises due to the presence water-mediated interaction that is
being neglected in many docking protocols.
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Very few Molecular Dynamics (MD) simulations have been performed for sulfated
GAGs such as heparin and HS. MD simulations have been performed for the complex of a
heparin pentasaccharide with AT-III in order to characterize the energetic contribution of
important amino acids required for the interaction with GAG fragments and the ability of
GAG fragments to induce the observed conformational change in AT-III.133
1.6.2. Molecular Docking of Small Organic Non-Carbohydrate Sulfated Molecules
Most of the research on sulfated molecules has been focused on GAGs due to their
extensive role in many physiological processes and disease conditions. This is based on the
assumption that a GAG sequence is a critical pharmacophore needed for recognition and
activation/inhibition of the target protein.
This concept was challenged by Gunnarsson et al. in Desai’s lab when they
designed a non-carbohydrate sulfated molecule to mimic the trisaccharide to activate
antithrombin.134 The rational design strategy is based on a study of complexes of natural
and mutant antithrombins with heparin-based oligosaccharides using hydropathic
interaction (HINT) technique, a quantitative computational tool for analysis of molecular
interactions.
Using this approach, a small, nonsugar, aromatic molecule, (-)-epicatechin sulfate
(ECS), was designed by Gunnarsson et al. to mimic the non-reducing end trisaccharide unit
DEF of the sequence specific heparin pentasaccharide DEFGH. The designed (-)epicatechin sulfate (ECS) was the first small non-saccharide molecule reported as an
activator of antithrombin for the accelerated inhibition of factor Xa, a key proteinase of the
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coagulation cascade.134 (+)-Catechin sulfate (CS), a chiral stereoisomer of ECS, was found
to be more active than the (-)-epicatechin sulfate (ECS).135 The molecular docking study
using HINT suggested plausible binding of CS in the extended heparin binding site, which
is adjacent to the binding domain for the reference trisaccharide DEF.135
Following this dramatic change in designing non-carbohydrate sulfated molecules,
many papers have been published by Desai’s lab describing new methodologies for
docking of sulfated molecules and advances in synthetic methods for efficient synthesis,
characterization and biological evaluation (more details in Chapter 2).
1.7.

Antithrombin-Based Anticoagulants

1.7.1. Antithrombin Structure and Mechanism of Inhibition
Clotting is a natural defense mechanism of the body to prevent excessive loss of
blood and ingestion of microbes upon injury. Yet, unintended clot formation can be very
dangerous and is a leading common cause of death. Anticoagulants are used
therapeutically in the treatment and prevention of clot formation and clot growth in
thromboembolic disorders.
Endogenous antithrombin (AT) is a major regulator of blood clotting. It inactivates
a number of proteinase enzymes of the coagulation cascade, especially thrombin and factor
Xa.136 Antithrombin alone is a poor inhibitor. However, heparin-based anticoagulants
enhance its proteinase inhibitory activity. Because of this, heparin-based anticoagulants are
also called antithrombin activators.
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Human antithrombin is a glycoprotein with 432 residues with major (αantithrombin) and minor form (β-antithrombin). Antithrombin is also a member of the
serine proteinase inhibitors (serpin) superfamily of proteins. It shows structural and
functional similarity with homologous serpin members including α1-proteinase inhibitor,
heparin co-factor II, and plasminogen activator inhibitor-I.137,138
The structure of intact, uncleaved, free antithrombin has nine α-helices surrounding
three β-sheets.139-141 There are two striking features: a dominant five-stranded β-sheet A,
approximately in the center of the inhibitor and an exposed 15-residue sequence called
reactive center loop (RCL) containing the reactive bond between Arg393 and Ser394 that
serves as the substrate for serine protease (Figure 5A). These features are common to all
serpins.137,138,142,143
Antithrombin has another unique feature known to be present in only one other
serpin, heparin co-factor II.144 Two residues, P15-P14 (Gly379-Ser380) at the N-terminal
end of the reactive center loop, are partially inserted as a short β-strand between strands 3
and 4 of β-sheet A (Figure 5A).
The overall structure of antithrombin cleaved at the reactive center loop (RCL) is
similar to the intact form, except that the RCL is inserted as strand 4a in β-sheet A (Figure
5B). This structural change results in the movement of the P1 residue to the opposite side
of the protein, a distance of approximately 70 Å. This dramatic conformational change
following cleavage by the target enzyme leads to significant thermodynamic stabilization
of the molecule.145,146
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Ser394
(P1′)

Arg393
(P1)
RCL

Gly379
(P15)
Ser380
(P14)

Arg393
(P1)

A. Native antithrombin

B. Cleaved antithrombin

Figure 5. Ribbon diagram of native (A) and cleaved (B) plasma antithrombin. The crystal
structure is from PDB entry 1ath. The Reactive Center Loop (RCL) is shown in red.
Reactive bond residues Arg393 (P1) and Ser394 (P1′) and the partial insertion loop Gly379
(P15) and Ser380 (P14) are shown in ball-and-stick representation. The P1 residue, in an
exposed orientation in the native structure, moves to the opposite end of the molecule
following cleavage with a proteinase, whereupon the RCL is inserted as strand 4 in 6stranded β sheet A. The proteinase moves with the P1 residue to the bottom of the inhibitor
and is covalently trapped. Adapted from Desai, U. R. New antithrombin-based
anticoagulants. Med Res Rev 2004, 24, 151-181.
A recent crystal structure of the α1-proteinase inhibitor–trypsin complex147 and
biochemical results148,149 indicate that the dramatic structural change following cleavage of
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the P1-P1′ bond is critical for the disruption of the catalytic triad of the proteinase, which
results in the inactivation of the enzyme.
Thrombin and factor Xa inhibition by antithrombin is referred to as the serpin
‘mousetrap’ mechanism. Antithrombin (AT) acts as a bait to trap the target enzyme (E) in
an equimolar, covalent, inactive complex (AT -E ). In the first step, the RCL interacts
with the active site of the proteinase to form a Michaelis complex (AT:E). This is rapidly
followed by cleavage of the scissile bond P1-P1’ in the RCL to form an acyl-enzyme
intermediate (AT-E), which undergoes a major rearrangement to disrupt the enzyme’s
catalytic triad147-150 resulting in inhibition (E -AT ) (Inhibition Pathway, Figure 6). In the
substrate pathway (Figure 6), structural perturbations in antithrombin (e.g., mutational
changes) may facilitate rapid hydrolysis of the acyl-enzyme intermediate E-AT to yield an
active enzyme (E) and a cleaved inhibitor (ATC) that diminishes efficacy of inhibition.

Figure 6. A model of the serpin ‘mouse trap’ mechanism of inhibition (See text for
details). Reproduced from Desai, U. R. New antithrombin-based anticoagulants. Med Res
Rev 2004, 24, 151-181.
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1.7.2. Rates of Antithrombin Inhibition of Thrombin and Factor Xa
The antithrombin inhibition of factor Xa and thrombin is a slow process. The
typical uncatalyzed in vitro thrombin inhibition rate at pH 7.4 and 25 °C is in the range of
7–11×103 M-1 sec-1,151-153 while for factor Xa, it is 2–3×103 M-1 sec-1.154 The slow rates of
factor Xa and thrombin inhibition are dramatically increased in the presence of heparin.
The second-order rate constant for thrombin inhibition by antithrombin–heparin complex
is in the range of 1– 4×107 M-1 sec-1, which is an acceleration of more than 2,000-fold, and
for factor Xa inhibition this constant reaches 1.5×106 M-1 sec-1 representing an increase of
~600-fold.155-158 Under physiological conditions, the acceleration of factor Xa inhibition
may be even higher due to the presence of calcium ions.159
1.7.3. Mechanism of Heparin Activation of Antithrombin
A two-step induced-fit mechanism is involved in antithrombin activation by the
high-affinity ligands heparin or heparin pentasaccharide (H5). In the first step, heparin
recognizes the native antithrombin (AT) and forms a low-affinity complex (AT:H) in rapid
equilibrium, then is followed by a major conformational change to give a high-affinity
complex (AT*:H).160
K1

:

K-2

:

Eq. (10)

K2

In equation 1, K1 is the rapid equilibrium constant of first step of the induced-fit
pathway; K2 and K-2 are forward and reverse rate constants for the conformational change
36

step. The conformational change results in the expulsion of the partially inserted RCL
residues. This significantly changes the conformation of the P1-P1′ reactive center loop
and exposes an exosite in antithrombin (Figure 7).150,154,157,158,161 This process is called the
conformational activation of antithrombin. The altered RCL in heparin-antithrombin cocomplex is better recognized by factor Xa resulting in accelerated cleavage of the P1-P1′
bond and rapid formation of the covalent inhibited complex (E*-AT* in Figure 6). Thus,
conformational activation of antithrombin is necessary and sufficient for accelerated factor
Xa inhibition.

factor Xa

AT

HBS

RCL

++++

+++
++
++++
- - - - - - - -

+++

-

factor Xa inhibition

RCL

factor IXa inhibition

++++
- - - - - - - - -

+

Ca2+, factor

AT : H complex
H5 sequence

IXa

+++++++
- - - - -- -

Ca2+

Gla domain

- - - - - - - - - - -

thrombin inhibition

Full-length Heparin
thrombin

++++
+++
- - - - - - - - - - -

Figure 7. Two major mechanisms of heparin activation of AT and subsequent inhibition of
factor Xa, factor IXa or thrombin: conformational activation and bridging mechanism.
AT*:H = antithrombin–heparin complex; H5 = high-affinity pentasaccharide sequence in
heparin; RCL = reactive center loop; ‘+++’ = exosite on enzyme; HBS = heparin-binding
site. Reproduced from Desai, U. R. New antithrombin-based anticoagulants. Med Res Rev
2004, 24, 151-181.
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Thrombin inhibition is accelerated only two-fold through the conformational
activation mechanism (Figure 7).158 The acceleration of thrombin inhibition by heparin
primarily arises from a bridging mechanism. The H5 sequence in full length heparin tightly
binds to antithrombin and is followed by the binding of thrombin to the same heparin chain
at non-specific sites to form an antithrombin–heparin–thrombin ternary complex (Figure
7). Thrombin then diffuses along the polyanionic chain to encounter the inhibitor. This
whole process results in a ~2,000-fold acceleration in inhibition under physiological
conditions. A saccharide length of ~18 residues is needed to simultaneously hold thrombin
and antithrombin for the accelerated inhibition.162-163 A sequence-specific H5 is necessary
for tight binding of heparin chains, but H5 alone cannot potentiate antithrombin inhibition
of thrombin.
1.7.4. Heparin Binding Site and Reactive Center Loop in Antithrombin
The heparin binding site in antithrombin is located about 20 Å away from the
reactive center loop. This binding site specifically recognizes a heparin pentasaccharide
sequence with high-affinity.158 The heparin-binding domain in antithrombin is formed by
positively charged residues of helices A and D, and the polypeptide N-terminus. The
crystal structure of antithrombin pentasaccharide co-complex (PDB entry 1AZX, (Figure
8) shows that residues Arg47, Lys114, Lys125, and Arg129 in this region are commonly
referred to as the pentasaccharide binding site (PBS), interact with H5.164 This observation
is also consistent biochemical studies with antithrombin mutants.165-169
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A. Antithrombin-H5 complex
PBS
Helix A

Arg46

H
G

D

E

Lys114

Arg129

Lys133

Lys136

Arg47

F

Helix P

Lys125

Helix D
Arg132
B. Close-up view

EHBS

Figure 8. Ribbon diagram of plasma antithrombin complexed with natural pentasaccharide
DEFGH (A) and a close-up view of the heparin-binding site (B). The crystal structure cocomplex is obtained from PDB entry 1azx. Ribbon in red is the RCL, and magenta is the
heparin-binding site. Pentasaccharide DEFGH is shown in ball-and-stick representation
and individual residues are identified. Helices D, P and A form the heparin-binding site
(HBS). Arg46, Arg47, Lys114, Lys125, and Arg129 form the pentasaccharide binding site
(PBS) and Arg132, Lys133, and Lys136 form the extended heparin-binding site (EHBS).
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A full-length heparin, in addition to interacting with PBS, also binds to an extended
region formed by the basic residues Arg132, Lys133, and Lys136 at the C-terminal end of
helix D (the EHBS).170
1.7.5. Heparin, LMWHs and Heparin Pentasaccharide DEFGH
Heparin is an anticoagulant that is a linear polysaccharide of varying chain length
and is composed of uronic acid and glucosamine residues that are variably sulfated and
acetylated.158,171-172 Although heparin is a commonly used anticoagulant, its use as an
anticoagulant is still limited by serious side effects such as excessive bleeding
complications.173
In addition to bleeding complications, unfractionated heparin (UFH) and low
molecular weight heparin (LMWH) suffer from significant intra- and inter-patient dose
variability that requires laboratory monitoring. Heparin-induced thrombocytopenia (HIT)
is a potentially lethal complication of heparin therapy that is associated with thrombosis.
HIT refers to a significant drop in platelet count between 4 and 14 days after the initiation
of therapy.174
Low Molecular Weight Heparins (LMWHs) is a better choice compared to heparin
as anticoagulant.175-177 LMWHs are much smaller in size (MR 4,000–6,000) and are
produced from heparin by chemical or enzymatic depolymerization. Ardeparin, dalteparin,
enoxaparin, nadroparin, reviparin and tinzaparin are examples of available LMWHs.178
In comparison to heparin, LMWHs have greater bioavailability at low doses, better
pharmacokinetics, and a more predictable dose response, which allows for fixed doses to
40

be administered without laboratory monitoring.175-181 However, the risk of bleeding is not
completely eliminated. In fact, there is not much difference between UFH and LMWHs
when comparing preoperative hemorrhagic risk.182-185 In addition, other concerns
originating from the structural variations of LMWHs still need to be addressed. For
example, different methods of preparation may introduce considerable variation in the in
vivo efficacy among the LMWHs.186 A report in 2007 revealed that heparin contaminated
with oversulfated chondroitin sulfate (OSCS) was responsible for at least 81 reported
deaths. Another concern arising from animal-derived heparin products due to the presence
of potentially toxic substances that have a chemical structure similar to heparin.187-192
A sequence-specific heparin pentasaccharide-based compound, Fondaparinux, is
perhaps the best anticoagulant in the heparin class due to the lack of HIT and a more
predictable patient response. It also is not completely devoid of the risk of bleeding and
lacks an effective antidote to reverse excessive iatrogenic bleeding.193-198 A new
pentasaccharide called idraparinux is being developed as a once-a-week injection, but
because of its structural similarity to fondaparinux it is likely to carry a similar bleeding
risk and antidote problem.199-201
Most of the side effect complications are attributed to the nature of structural
complexity and diverse roles of heparin and heparan sulfate in a number of physiological
and pathological processes. These side effects are reduced by using homogeneous heparin
preparations such as fondaparinux, which is a synthetic five-residue sequence based on the
naturally occurring DEFGH sequence (Figure 9).
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H5 consists of three 2-N- and 6-O-sulfated glucosamines (β-D-GlcNp2S6S; residues
D, F, H) interspersed with a 2-O- sulfated iduronic acid (α-L-IdoAp2S; residue G) and a
glucuronic acid (β-D-GlcAp; residue E), in which the central glucosamine residue F has a
unique 3-O-sulfate group (Figure 10). This sequence is abbreviated as GlcNp2S6S (1 → 4)
IdoAp2S (1 → 4) GlcNp2S3S6S (1 → 4) GlcAp (1 → 4) GlcNp2S6S and labeled as
DEFGH, in line with the history of its identification.202-205
Detailed structure-activity studies show that several anionic groups of DEFGH are
critical for its high-affinity interaction with antithrombin (Figure 9).206 More importantly,
studies with truncated variants of DEFGH indicate that trisaccharide sequence DEF is the
minimum structure that retains the functional role of heparin, i.e., antithrombin activation,
albeit with significant loss of affinity under physiological conditions.206
The multidimensional limitations associated with heparin based anticoagulants
warrants the need for the design of newer anticoagulants. For example, antithrombin (AT)based anticoagulants including heparin, low molecular weight heparin (LMWH) and
fondaparinux (FX)207 are only effective when administered parenterally. Compared to
heparin or LMWHs, results from clinical trials with fondaparinux are more promising with
a low probability of causing HIT (Heparin Induced Thrombocytopenia) but its long term
efficacy and safety is yet to be ascertained.208 In addition, fondaparinux does not interact
with protamine sulfate, the heparin antidote, making it difficult to manage drug-induced
bleeding. However, the initial success of fondaparinux has validated factor Xa as a target
for antithrombin-based anticoagulants.
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Heparin or Low Molecular Weight Heparins

D

E

F

G

H

DEFGH Sequence

Figure 9. Structure of a heparin chain/LMWHs, and the sequence-specific heparin pentasaccharide DEFGH. Note the
variations in the structure of glucosamine (GlcNp) and uronic acid residues (IdoAp or GlcAp). Numbers 1 and 4 refer to
saccharide positions and the 1→4 linkages. Groups in magenta are critical for high affinity interaction with antithrombin.
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1.8.

Designing Synthetic Non-Sugar Antithrombin Activators

1.8.1. Hypothesis
Our research group has challenged the assumption that the saccharide-based
skeleton is essential for the activity of specific glycosaminoglycan (GAG) sequences. We
hypothesized that specific GAG sequences can be replaced by non-saccharide skeletons
which may provide several advantages over the GAG skeleton. These include 1) ease of
chemical synthesis, 2) likelihood of oral delivery due to enhanced hydrophobic character,
3) opportunity to gain additional non-ionic binding energy, 4) enhanced specificity for the
target protein and 5) the ability to modulate responses in either an agonist or an antagonist
manner. The following sections describe the methodologies used and the advances made in
designing non-saccharide antithrombin activators.
1.8.2. First Generation Non-sugar Antithrombin Activators
Numerous attempts have been made to design or discover new molecules that
activate antithrombin.158,160,207 However, each of these searches has relied on utilizing a
saccharide scaffold as a mimic of heparin. Implicit in these designs was the expectation
that a saccharide scaffold was necessary to induce antithrombin activation.
Designing non-saccharide, antithrombin activators is not an easy task for some
critical reasons. As mentioned earlier, antithrombin activation is a two-step induced-fit
process that involves an initial recognition phase and followed by conformational
transformation of AT.160,206 Mimicking such a two-step process by design is challenging.
Heparin mimics invariably must possess several negative charges, which can induce
44

recognition of many electropositive domains on protein surfaces, leading to potential
unwanted side effects. Mimicking heparin, or even pentasaccharide DEFGH (~20–25 Å
long), by substituting organic scaffolds with multiple sulfate and carboxylate groups
presents substantial design and synthetic challenges.209
Desai and co-workers have shown through structure-activity relationship studies
that, while residues D, E, F, G, and H of the pentasaccharide sequence are required for
high-affinity binding (50 nM) and complete activation (300 fold) of antithrombin, residues
D, E and F can bring about full activation at 1000 fold higher concentrations (Figure 10
A).206 Thus, based on the trisaccharide DEF as a template, small, non-saccharide sulfated
flavans were designed by Gunnarsson et al. using hydropathic interaction (HINT)210
analysis (Figure 10B).
These designed molecules were found to be weak activators of the inhibitor AT
(~10 fold).134 The results indicated that sulfated flavans bind to AT with an affinity
between 18 and 500 μM and bind in the adjoining extended heparin-binding site instead of
the targeted pentasaccharide-binding site in AT.135 This result explains the weak activation
of AT. In order to determine structure-activity relationships, several analogs of sulfated
flavans including sulfated flavones were synthesized (Figure 10B).
However, initial synthetic efforts towards sulfated flavones were unproductive
because these non-saccharide designs possess significantly greater charge density than
GAGs.211 Hence, Gunnarsson et al. developed an alternate synthetic route to sulfated
flavones that involved reductive cleavage of 2,2,2-trichloroethyloxysulfonyl-protected
flavonoids (Figure 11).212 Using this method, six sulfated flavones bearing different sulfate
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group distributions were synthesized and evaluated. These sulfated flavans and flavones
were also found to bind non-specifically to the smaller extended-heparin binding site in AT
and resulted only in weak activation of antithrombin.

A. DEF sequence

B. Sulfated flavans and flavones
Figure 10. A) Structure of the DEF fragment. Critical groups for binding to antithrombin
are shown in magenta. B) Non-saccharide DEF mimics.

Figure 11. TCE-protection-deprotection strategy for the synthesis of sulfated flavones
[TCE = 2,2,2–trichloroethyloxysulfonyl (CCl3CH2OSO2−)].
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1.8.3. Tetrahydroisoquinoline-Based Lead Compounds
To improve on the antithrombin activation potential of these organic activators, a
tetrahydroisoquinoline-based bicyclic-unicyclic sulfated activator IAS5 (Figure 12) was
designed using a pharmacophore-based approach (Figure 12). The pharmacophore was
extracted from DEF and four critical groups were connected in three-dimensional space
using a linear carbon linker to arrive at a first ‘blueprint’ of an activator.209,213
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Figure 12. Rationale used in the design of tetrahydroisoquinoline-based organic activator
IAS5. Four critical anionic groups (highlighted as filled ovals) of trisaccharide DEF formed
the pharmacophore. Connecting the groups using a carbon framework followed by
engineering of rigidity that matches their orientation gave rise to a ‘blueprint’, which was
transformed into a synthetically plausible target, IAS5. Reproduced from Raghuraman, A.;
Liang, A.; Krishnasamy, C.; Lauck, T.; Gunnarsson, G. T.; Desai, U. R. On designing nonsaccharide, allosteric activators of antithrombin. Eur J Med Chem 2009, 44, 2626-2631.
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IAS5, the tetrahydroisoquinoline-based activator containing an acid functionality
and five sulfate groups was synthesized from commercially available precursors by
Raghuraman et al.209 These studies showed that IAS5 activates antithrombin nearly 30-fold,
an increase of nearly 2 to 3-fold higher than the first-generation rationally designed
agents.134,135
The previously reported non-saccharide antithrombin (AT) activators in our
laboratory, including sulfated flavonoids and sulfated tetrahydroisoquinoline derivatives,
were found to bind the extended heparin-binding site (EHBS), although they were
designed to target the pentasaccharide-binding site (PBS). The affinity capillary
electrophoretic based competitive binding assays developed by our lab (Dr. Aiye Liang)
showed that the tetrahydroisoquinoline-based molecules do not compete with a high
affinity heparin pentasaccharide. In contrast, the affinity decreased dramatically in the
presence of an extended heparin binding site ligand.214
The X-ray crystal structures of antithrombin alone215,216 and in complex with
heparins217,218 show that the PBS is exposed to solvent, implying that the binding domain
should be freely available. Yet, biochemical studies in solution show that the N-terminus
of the polypeptide overlays on the PBS.219 This implies that the three key residues, Lys114,
Lys125 and Arg129, are not readily accessible to ligands in solution. Thus, it is likely that
sub-optimal activators that cannot engage all three key residues find it difficult to form a
productive PBS-based antithrombin–ligand initial recognition complex167-169 that can
initiate the induced-fit conformational change in the serpin. Rather, the sub-optimal
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activators are ensnared by an adjacent electropositive domain, the EHBS, resulting in
lower activation.
1.8.4. Questions Remaining Unanswered
The

previously

reported

non-saccharide

sulfated

flavans

and

tetrahydroisoquinoline-based molecules are binding at the EHBS of activated antithrombin
and are weak activators of antithrombin. Thus, the questions that arise include: Can we
design molecules that bind in the PBS of activated antithrombin with high affinity?
Further, can we design molecules that interact with the PBS of activated antithrombin with
high specificity? Chapter 2 describes the computational and experimental methodologies
used to address these questions.
1.9.

Desinging Specific Thrombin Exosite-II Modulators
As mentioned earlier, heparin is a complex carbohydrate biopolymer made of linear

polysaccharides of varying chain length and is composed of uronic acid and glucosamine
residues.113 Although heparin is a commonly used anticoagulant it suffers from serious side
effects such as excessive bleeding complications, heparin induced thrombocytopenia, and
significant intra- and inter-patient dose response variability.173,174
Most of the side effect complications arise primarily from its structural complexity
and its interaction with numerous proteins other than coagulation proteins factor Xa (fXa),
thrombin, and antithrombin. Implicitly these diverse roles must arise from an optimal
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combination of specificity and affinity. However with the exception of a few cases, the
specificity of heparin interactions has been poorly understood and not explored in detail.
In antithrombin, three important amino acids are involved in heparin
pentasaccharide binding, while in thrombin, at least seven basic amino acids are predicted
to be involved. For biological systems, one would expect greater specificity with more
interacting points. However, the heparin–thrombin system interestingly displays a lack of
specificity. The molecular basis for this lack of specificity is not clear.
1.9.1. Questions Remaining Unanswered
The heparin binding sites (HBS) of antithrombin and thrombin are lined with Arg
and Lys residues. Whereas the antithrombin-heparin interaction is specific, the thrombinheparin interaction is considered to be non-specific. Thus, the questions that arise include:
What is the structural and molecular basis for the specificity of the antithrombin-heparin
interaction and the non-specificity of the thrombin-heparin interaction? Is it possible to
design ligands that are specific for thrombin exosite-II?
Chapter 3 describes the structural biology and molecular modeling approaches used
to study the specific and nonspecific interactions of heparin with antithrombin and
thrombin. Also the mehodolgies used in designing specific thrombin exosite-II ligands
using molecular docking techniques have been described.
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CHAPTER 2
VIRTUAL SCREENING OF TETRAHYDROISOQUINOLINE
SCAFFOLD AS ANTITHROMBIN ACTIVATORS

2.1.

Virtual Screening of a Library of Tetrahydroisoquinolines
As mentioned in Chapter 1, the previously designed small, sulfated non-saccharide

molecules are binding to the extended heparin binding site (EHBS) of antithrombin. Thus,
they are poor activators of antithrombin. The lack of ability of the small, sulfated nonsaccharide molecules to fully activate the antithrombin could be remediated by devising a
credible non-saccharide design strategy that would facilitate the design of better nonsaccharide anionic molecules with appropriate charge distribution with which to engage
the the pentasaccharide binding site (PBS) amino acids residues Lys114, Lys125 and
Arg129, and thus, turn the ‘key’ to open the ‘lock’.
As mentioned in Chaper 1, the design of sulfated flavonoids and sulfated
tetrahydroisoquinoline derivatives was based on the structure of trisaccharide DEF. It was
time-consuming and user-biased because it involved manual pre-positioning of the ligand
in the pentasaccharide-binding site in AT. This reduces the number of structural variations
that could be effectively tested.
In addition, to increase our chances of targeting the PBS, we decided to use an
approach that would categorize the ligands as either PBS-binding or EHBS-binding
structures in AT (native and activated AT).
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Also, to explore a large number of

possibilities, such a method would have to be rapid and automated. Virtual screening (VS)
was selected as the most appropriate method to achieve the aforementioned goals. VS is a
computational technique that involves the rapid in silico assessment of large libraries of
chemical structures in order to identify those structures most likely to bind to a drug target,
typically the protein receptor or enzymes.
We have used the GOLD docking program for virtual screening of molecules
bearing the tetrahydroisoquinoline scaffold with customized fitness functions to identify
the hit molecules in an efficient manner, and also with high degree of reproducibility.
VS of the tetrahydroisoquinolines included the following components: i)
constructing a library of tetrahydroisoquinoline based compounds using LEGION, ii)
structural optimization and energy-minimization of the tetrahydroisoquinoline library for
docking, iii) molecular docking of the library of compounds using the GOLD docking
program onto activated and native antithrombin at the pentasaccharide biding site (PBS)
and extended heparin binding site (EHBS), iv) identifying and analyzing the hit molecules
and the core structural features proposed to be necessary for AT binding, v) analysis of
protein-ligand interactions and their putative binding modes.
2.1.1. Designing Virtual Tetrahydroisoquinoline (ISOQ) Library
The success of combinatorial virtual library screening for glycosaminoglycans
(GAGs) using GOLD in our lab suggested that it should be possible to use the previously
reported protocol with modifications to study the tetrahydroisoquinoline based bicyclic52

unicyclic chemical structures for antithrombin activation. The core structure is derived
from the tetrahydroisoquinoline-based compound IAS5 (Figure 12). In order to find the
appropriate position of sulfate group, substitutions were allowed at different positions. This
library also consisted of 16 types of linkers (L) to study the effect of type and size of
different linkers that connects the tetrahydroisoquinoline and phenyl ring system on
antithrombin affinity. This combination of linkers and variation in the substitution pattern
in the rings (S1 to S9 and X, Figure 13) resulted in a virtual library of 24576 compounds.

L: Linker, S1 to S9: H/-OSO3−,
X: H/COO− (Both R- and S-isomers included)
–CO– (keto),
–CONH–(amide),
–CH2– (methylene),
–CH2CH2– (ethylene),
–CH2CH2CH2– (n-propylene),
–CH=CH– (ethenyl),
–CH=CHCH2– (1-propenyl, allyl)
–CH2CH=CH– (2-propenyl, isoallyl),

–CH2CH2CH2CH2– (n-butylene)
–CH2CH2CH2CH2CH2– (n-pentylene)
–CH2CH2CH2CH2CH2CH2– (n-hexylene)
–CH=CHCH2CH2– (1-butenyl)
–CH2CH=CHCH2– (2-butenyl)
–CH2CH2CH=CH– (3-butenyl)
–CH=CHCH2CH2CH2– (1-pentenyl)
–CH2CH2CH2CH=CH– (4-pentenyl)

Figure 13. Combinatorial virtual library based on IAS5 with linkers containing 1 to 6
atoms. The library was created by variation of substituents S1 to S9, X, and the linker L.
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VIRTUAL LIBRARY DESIGN
24576 ISOQ Virtual

Docking of Virtual Library (GOLD)
‘Affinity Filter’
10,000 GA iterations, one run per compound
Docking onto Activated Antithrombin
Pentasaccharide Binding Site (PBS)

High Scoring Compounds
User‐defined

NO

DISCARD

GOLD Score ≥ 100
YES
Docking of Virtual Library (GOLD)
‘Specificity Filter’
100,000 GA iterations, 3 runs per compound
Docking onto Activated Antithrombin
Pentasaccharide Binding Site (PBS)
Docked in Triplicate
RMSD ≤ 2.5 Å

Docking the Hits
onto EHBS
GOLD Score
EHBS < PBS

YES

YES

NO
DISCARD

Docking the Hits
onto Native AT

‘High Affinity’ and ‘High
Specificity’ Hit
Compounds

‘High Affinity’, ‘High
Specificity’ Hit
compounds

GOLD Score
Native < act PBS

NO
DISCARD

Figure 14. Docking protocol used to screen a combinatorial library of 24576
tetrahydroisoquinoline-based compounds. Color filled box: general dual-filter algorithm.
(See text for details).
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Molecular modeling of the combinatorial virtual library was performed using
SYBYL (Tripos, St. Louis, MO). The small molecule non-saccharide library was built
using the LEGION combinatorial library design module. LEGION rapidly generates 2D
structures in SYBYL Line Notation (SLN) in a combinatorial manner. A plausible 3D
geometry of the 2D structures generated by LEGION was obtained using CONCORD and
these structures were subjected to energy minimizations (Section 2.9.2) in an automated
manner using in-house SYBYL Programming Language (SPL) scripts. The SPL scripts
were written to simultaneously modify the atom and bond types of the sulfate groups so
that they were identical to the types used for GAGs. The protocol used for virtual
screening of non-saccharide molecules was identical to the previously reported dual-filter
algorithm used for saccharides, but with additional functions (Figure 14).109
2.2.

Docking of ISOQ Library onto Activated Antithrombin (PBS and EHBS)
Previous studies in our lab on the docking of the H5 sequence and its variants to the

activated crystal structure of AT predicted that the modified GOLDScore (see
experimental methods) of the H5 sequence is 140 and its binding geometry was repeatedly
predicted to within 2.5 Å in multiple docking experiments.109 Thus, our search for small
organic activators used these benchmarks as targets.
We docked these virtual 24576 molecules onto the activated form of antithrombin
(PDB entry 1TB6) as mentioned in the docking protocol.109,248 Following the affinity filter
step, a normal Gaussian distribution of molecules was noted, as expected, with the
majority showing poor binding to antithrombin (Figure 15).
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Figure 15. Histogram depicting the distribution of modified GOLDScore in 10 unit
intervals for the 24576 tetrahydroisoquinoline compounds docked onto activated
antithrombin PBS following the first phase (affinity filter) of the dual-filter screening
algorithm.
The virtual 24576 molecules were docked to the pentasaccharide binding site (PBS)
of antithrombin in affinity filter step (10,000 iterations). The molecules that had GOLD
score greater than 100 (GOLD score for DEF = 115, while that for DEFGH = 140) were
then docked in triplicate (100,000 iterations) onto the activated form of AT with
‘specificity’ as the second filter, where only 211 molecules passed the 2.5 Å cut-off filter
(i.e., the top ranked 2 solutions were within 2.5 Å in each run). Of these 211 molecules,
only 92 molecules passed the stringent test of specificity filter (The RMSD of the top
ranked 2 solutions from each run and across runs is within 2.5 Å (Table 2: RMSD data for
92 hit compound, a measure of ‘specificity’ (At the end of this chapter with experimental
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section). Thus, our combinatorial virtual screening results indicate that 92 molecules are
likely to bind in the PBS of activated antithrombin with good affinity (Table 1).
Table 1. Modified GOLDScore for 92 hit compounds and their structural information.
Compounds with 1-Carbon Linker

Compound ID
ISOQ_6162
ISOQ_R_6082
ISOQ_S_6153
ISOQ_S_6330

ISOQ
Ring
5, 6
5,6
5,6
5,6,8

Carboxylate
Group
−
(R) COO−
(S) COO−
(S) COO−

Phenyl
Ring
2′,3′,6′
2′,4′
2′,3′
3′

Total
Charge
−5
−5
−5
−5

Mod. GOLD
Score
108
104
107
107

Phenyl
Ring
2′,3′,4′
2′,4′,5′

Total
Charge
−6
−6

Mod. GOLD
Score
102
117

Compounds with 2-Carbon Linker

Compound ID
ISOQ_S_1873
ISOQ_S_4255

ISOQ
Ring
6,8
5,8

Carboxylate
Group
(S) COO−
(S) COO−
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Compounds with−CONH− Linker

Compound ID
ISOQ_R_1059
ISOQ_R_277
ISOQ_R_5183
ISOQ_R_5218
ISOQ_R_5325
ISOQ_S_2072
ISOQ_S_6463
ISOQ_S_6623
ISOQ_S_7547
ISOQ_S_7832

ISOQ
Ring
7, 8
7
5,7,8
5,7,8
5,7,8
6,8
5,6,8
5,6,8
5,6,7,8
5,6,7,8

Carboxylate
Group
(R) COO−
(R) COO−
(R) COO−
(R) COO−
(R) COO−
(S) COO−
(S) COO−
(S) COO−
(S) COO−
(S) COO−

Phenyl
Ring
2′,3′,6′
2′,4′,5′
2′
2′,3′
2′,5′
2′,5′
2′,5′
2′,4′
3′,4′
2′,4′,6′

Total
Charge
−6
−5
−5
−5
−6
−5
−6
−6
−7
−8

Mod. GOLD
Score
116
109
109
119
121
108
127
117
121
117

Phenyl
Ring
2′,4′
3′,4′
2′,5′

Total
Charge
−4
−5
−6

Mod. GOLD
Score
113
105
120

Compounds with 3-Carbon Linker

Compound ID
ISOQ_5809
ISOQ_R_1960
ISOQ_S_6652

ISOQ
Ring
5,6
6,8
5,6,8

Carboxylate
Group
−
(R) COO−
(S) COO−
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Compound ID
ISOQ_1903
ISOQ_2561
ISOQ_6435
ISOQ_R_1875
ISOQ_R_2106
ISOQ_R_5769
ISOQ_R_6018
ISOQ_R_6053
ISOQ_R_6408
ISOQ_S_6960

Compound ID
ISOQ_2096
ISOQ_S_5963
ISOQ_S_6159

ISOQ
Ring
6,8
6,7
5,6,8
6,8
6,8
5,6
5,6
5,6
5,6,8
5,6,7

Carboxylate
Group
−
−
−
(R) COO−
(R) COO−
(R) COO−
(R) COO−
(R) COO−
(R) COO−
(S) COO−

Phenyl
Ring
2′,5′
3′,4′,5′
3′
2′,3′,4′
2′,4′
3′
2′
2′,5′
3′,4′
2′,5′

Total
Charge
−4
−5
−4
−6
−5
−4
−4
−5
−6
−6

Mod. GOLD
Score
118
109
112
111
106
109
107
117
120
114

ISOQ
Ring
6,8
5,6
5,6

Carboxylate
Group
−
(S) COO−
(S) COO−

Phenyl
Ring
2′,4′
2′,4′,5′
2′,3′

Total
Charge
−4
−6
−5

Mod. GOLD
Score
106
117
108
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Compounds with 4-Carbon Linker

Compound ID

ISOQ
Ring
ISOQ_EXT_S_6462 5,6
ISOQ_EXT_5142
5,7
ISOQ_EXT_6294
5,6
ISOQ_EXT_6550
5,6
ISOQ_EXT_R_3182 6,7
ISOQ_EXT_R_6318 5,6
ISOQ_EXT_R_6542 5,6

Carboxylate
Group
(S) COO−
−
−
−
(R) COO−
(R) COO−
(R) COO−

Phenyl
Ring
2′,3′,6′
2′
2′,5′
2′,3′,6′
3′,4′
3′,5′
2′,3′

Total
Charge
−6
−3
−4
−5
−5
−5
−5

Mod. GOLD
Score
124
101
123
123
117
117
121

Compound ID

Carboxylate
Group
(S) COO−
(R) COO−
(R) COO−

Phenyl
Ring
3′,4′
2′,5′
3′,4′

Total
Charge
−4
−5
−5

Mod. GOLD
Score
113
115
117

ISOQ
Ring
ISOQ_EXT_S_1229 7
ISOQ_EXT_R_2861 6,8
ISOQ_EXT_R_6253 5,6
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Compound ID
ISOQ_EXT_S_6185
ISOQ_EXT_3201
ISOQ_EXT_6225
ISOQ_EXT_R_6217
ISOQ_EXT_R_6281
ISOQ_EXT_R_6297
ISOQ_EXT_R_6345
ISOQ_EXT_R_6409
ISOQ_EXT_R_6473
ISOQ_EXT_R_6857
ISOQ_EXT_R_6921

Compound ID
ISOQ_EXT_S_1243
ISOQ_EXT_S_6411
ISOQ_EXT_S_6971
ISOQ_EXT_S_6987
ISOQ_EXT_6467
ISOQ_EXT_979
ISOQ_EXT_R_6411
ISOQ_EXT_R_6443
ISOQ_EXT_R_6555
ISOQ_EXT_R_6955
ISOQ_EXT_R_731

ISOQ
Ring
5,6
6,7
5,6
5,6
5,6
5,6
5,6
5,6
5,6
5,6,8
5,6,8

Carboxylate
Group
(S) COO−
−
−
(R) COO−
(R) COO−
(R) COO−
(R) COO−
(R) COO−
(R) COO−
(R) COO−
(R) COO−

Phenyl
Ring
3′
3′
2′,4′
4′
3′
2′,5′
3′,4′
2′
2′,5′
3′,4′
2′

Total
Charge
−4
−3
−4
−4
−4
−5
−5
−4
−5
−6
−5

Mod. GOLD
Score
129
108
110
112
117
120
126
118
124
122
123

ISOQ
Ring
7
5,6
5,6,8
5,6,8
5,6
8
5,6
5,6
5,6
5,6,8
8

Carboxylate
Group
(S) COO−
(S) COO−
(S) COO−
(S) COO−
−
−
(R) COO−
(R) COO−
(R) COO−
(R) COO−
(R) COO−
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Phenyl
Ring
2′,4′,5′
2′
2′,3′,6′
2′,4′
2′,4′
2′,3′,4′,6′
2′
2′,5′
2′,3′,6′
2′,5′
2′,3′,6′

Total
Charge
−5
−4
−7
−6
−4
−5
−4
−5
−6
−6
−5

Mod. GOLD
Score
118
113
138
132
110
123
121
127
125
132
120

Compounds with 5-Carbon Linker

Compound ID

ISOQ
Ring
ISOQ_EXT_S_6815 5,6,8
ISOQ_EXT_855
8
ISOQ_EXT_R_2591 6,8
ISOQ_EXT_R_3279 6,7
ISOQ_EXT_R_6687 5,6,8

Carboxylate
Group
(S) COO−
−
(R) COO−
(R) COO−
(R) COO−

Phenyl
Ring
2′,5′
2′,4′,6′
2′
3′,4′
2′

Total
Charge
−6
−4
−4
−5
−5

Mod. GOLD
Score
129
108
110
121
125

Compound ID

Carboxylate
Group
(S) COO−
(S) COO−
−
−
−
−
−
−
−
(R) COO−
(R) COO−
(R) COO−

Phenyl
Ring
2′,4′
2′
2′,5′
2′,3′,6′
2′,4′
2′
2′,5′
3′,4′
2′
2′
2′,4′
2′,3′

Total
Charge
−5
−4
−4
−5
−4
−3
−4
−3
−5
−4
−5
−5

Mod. GOLD
Score
121
105
121
119
125
107
118
111
112
120
127
128

ISOQ
Ring
ISOQ_EXT_S_6234 5,6
ISOQ_EXT_S_6410 5,6
ISOQ_EXT_2850
6,8
ISOQ_EXT_2866
6,8
ISOQ_EXT_3906
6,7,8
ISOQ_EXT_6402
5,6
ISOQ_EXT_6434
5,6
ISOQ_EXT_706
8
ISOQ_EXT_7938
5,6,7,8
ISOQ_EXT_R_6170 5,6
ISOQ_EXT_R_6474 5,6
ISOQ_EXT_R_6538 5,6
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Compound ID
ISOQ_EXT_S_6236
ISOQ_EXT_S_6988
ISOQ_EXT_6532
ISOQ_EXT_R_2956
ISOQ_EXT_R_6444
ISOQ_EXT_R_6732
ISOQ_EXT_R_6988

ISOQ
Ring
6
5,6,8
5,6
6,8
5,6
5,6,8
5,6,8

Carboxylate
Group
(S) COO−
(S) COO−
−
(R) COO−
(R) COO−
(R) COO−
(R) COO−

Phenyl
Ring
2′,4′
2′,4′
2′,3′
2′,3′
2′,5′
4′
2′,4′

Total
Charge
−4
−6
−4
−5
−5
−4
−6

Mod. GOLD
Score
113
120
118
111
119
106
131

Carboxylate
Group
(S) COO−
−
(R) COO−
(R) COO−

Phenyl
Ring
2′,5′
2′,3′,6′
2′,4′
4′

Total
Charge
−5
−6
−5
−4

Mod. GOLD
Score
123
132
118
109

Compounds with 6-Carbon Linker

Compound ID
ISOQ_EXT_S_6448
ISOQ_EXT_7064
ISOQ_EXT_R_3408
ISOQ_EXT_R_6224

ISOQ
Ring
5,6
5,6,8
6,7
5,6
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2.2.1. Can these hit molecules preferentially bind to PBS and not to EHBS?
Experimental evidence clearly showed that (-)-epicatechin sulfate, one of the
reported earlier lead compounds, has reasonably good binding affinity with antithrombin
but weaker activation. It has been found that epicatechin and related molecules that were
designed and synthesized in our lab are able to bind antithrombin tightly, but unable to
activate is due to fact that they were binding in the EHBS of antithrombin and not PBS.
Docking results of these newly designed molecules (ISOQ-hits) in contrast are
showing GOLD scores equivalent to DEF and DEFGH on PBS of activated antithrombin.
In order to confirm that these compounds are indeed preferentially binding in the PBS but
not in the EHBS, we have docked the hit molecules onto EHBS of activated antithrombin.
The binding site has been predefined to include only the EHBS, so that GOLD docking of
hit molecules is guided into the EHBS. Out of 92 hits that recognize the PBS consistently,
90 of them do not recognize the EHBS consistently in triplicate, indicating that our hit
molecules are predicted to bind only the PBS and not the EHBS.
Only 2 molecules, ISOQ_5809 and ISOQ_EXT_R_6542 were predicted to have
significant affinity for both binding sites. However, the comparison of the GOLD scores
and binding geometries at PBS and EHBS of these 2 molecules (Figure 16 and Table 3)
shows that these molecules also tend to be docked preferably at the PBS, and not to the
EHBS.
ISOQ_EXT_R_6542 is taken as a model for explaining the preferential binding to
PBS and not to EHBS. Figure 19 show that the predicted binding geometry in the EHBS
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makes minimal interactions, whereas the predicted geometry in PBS has the maximal
number of interactions.

Table 3. Predicted interaction profile for hit ISOQ_EXT_R_6542 in PBS and EHBS

Binding site

Ligand group
2′-O-sulfate
3-Carboxylate
5-O-sulfate

Amino acid
Arg129
Lys125
Lys125
Lys114
Lys114
Arg47
Arg46
Arg132
Arg129
Lys133
Lys125

PBS
6-O-sulfate

2′-O-sulfate
5-O-sulfate
EHBS
6-O-sulfate
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Distance in Å
2.8
3.5
3.1
3.0
3.0
2.7
3.1
2.5
3.0
3.4
2.7

PBS

EHBS
GOLD Score: 94
Lys133

Lys136

Arg129

Arg132
PBS
GOLD Score: 121
Arg46

Arg47
EHBS

Arg129
Lys114
Lys125

Figure 16. Predicted binding geometry for hit ISOQ_EXT_R_6542 in PBS and EHBS. A.
Hit 6542 is shown in cyan stick form. B. Hit 6542 is shown green ball-and-stick form. In
both figures, heparin binding amino acids are shown in capped stick form in orange and
the helices A and D in magenta. The pentasaccharide sequence is shown in capped stick
form in SYBYL atom type color, for reference.
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This study predicts that indeed these compounds would preferentially bind at PBS
and not at EHBS. This finding that our newly designed molecules predicted to be
preferably binding at PBS, and not on EHBS, is a key in activation of antithrombinmediated indirect fXa inhibition. As mentioned earlier, previous lead compounds from our
lab (epicatechin and related compounds) are able to bind antithrombin tightly, but are
weakly activating antithrombin; this is due to the binding of these molecules at EHBS, and
not at PBS. Docking experiments of these newly designed molecules suggest that these hit
molecules bind at PBS and are approximately equivalent to DEFGH in GOLD score.
2.3.

Docking onto Native Antithrombin
As discussed earlier, a two-step induced-fit mechanism is involved in antithrombin

activation by the high-affinity heparin or a heparin pentasaccharide (H5). In the first step,
heparin recognizes the native antithrombin (AT) and forms a low-affinity complex (AT: H)
in rapid equilibrium, then is followed by a major conformational change to give a highaffinity complex (AT*:H). The conformational change results in the expulsion of the
partially inserted RCL residues. This is called conformational activation of antithrombin.
The conformationally activated antithrombin recognizes the factor Xa better, thus
increasing the effectiveness of the inhibition.
2.3.1. Can the ISOQ hits produce the necessary conformational changes in AT as H5
does?
To predict whether or not this can happen, we docked our 92 hit compounds in
triplicate onto the native antithrombin PBS (PDB entry 2ANT)141 to see if they have any
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preferential binding to the native form of antithrombin. These molecules were in general
had lower GOLD scores when docked to native antithrombin. Also they were not docked
consistently as in the PBS of activated form. This can be interpreted to mean that they are
mimicking the initial recognition (low affinity complex formation) with the native
antithrombin. Since the conversion of native antithrombin to activated antithrombin
happens in rapid equilibrium, it is hard to say how much GOLD score would be required to
bring about this change.

Compound

GOLD score for
native AT
ISOQ_R_277
93
ISOQ_R_6018
107
ISOQ_EXT_R_6411
92

GOLD score for
activated AT
109
107
121

Figure 17. Structures of ISOQ_R_277, ISOQ_R_6018 and ISOQ_EXT_R_6411 that are
docked consistently to both native and activated forms of antithrombin in triplicate
docking experiments. Groups in magenta shows the structural similarity between
ISOQ_R_6018 and ISOQ_EXT_R6411.
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Interestingly, there are 3 molecules of the 92 hit docked onto native antithrombin in
triplicate experiments within 2.5 Å RMSD: ISOQ_R_277, ISOQ_R_6018 and
ISOQ_EXT_R_6411 (Figure 17). Comparison of GOLD scores for ISOQ_R_6018 and
ISOQ_EXT_R_6411 in native and activated antithrombin shows an interesting
phenomenon. Both structures are structurally very similar, except that the hit 6411 has a 4carbon linker and a double bond close to the phenyl ring, whereas the hit 6018 has a 3carbon linker and a double bond close to the bicyclic ring.

Arg47

Arg46
Arg47

Arg46

Lys114

Arg129
Arg132

Lys114
Lys125

Arg129

Lys125

Lys136
Lys133

Arg132

Figure 18. Predicted binding geometry for hit ISOQ_R_6018 and ISOQ_EXT_R_6411 in
the PBS of activated antithrombin. Hit 6411 shown in cyan capped stick and hit 6018 in
green. Activated antithrombin heparin-binding amino acids (labeled in black) are shown in
capped stick form in orange and the helices A, D and P in magenta; whereas native form
amino acids are shown in capped stick form in white (labeled in red), and the helices A and
D in tan. The protein-ligand interactions are circled. Note the differences in orientation of
heparin binding amino acids in native and activated antithrombin.
69

The predicted binding mode of both the compounds are similar as shown in Figure
18, except that the phenyl ring orientation is better for hit 6411, perhaps due to the π-bond
effect in the phenyl ring end (3-ene) placing the ring system more appropriately to gain
hydrophobic interaction with the long side chain of the spatially conserved Arg129 (see
detail in Chapter 3, Section 3.4.1). This explain why the GOLD scores in the PBS of
activated thrombin for the hit 6018 with a short linker (3-carbon) and the hit 6411 with an
extended linker (4-carbon, thus the notation EXT for 4 or more carbon length) are 107 and
121, respectively.
Interestingly, the hit 6018 with a 3-carbon linker has the better GOLD score of 107
for native antithrombin than the hit with a 4-carbon linker that has the GOLD score of 92
for native, but a better profile for activated antithrombin. A closer look at the predicted
binding geometries of these hit molecules show that the short linker hit 6018 interacts with
Arg129, Lys125 and Arg47 of native antithrombin well within H-bond distances.
However, the extended linker hit 6411 makes only a few interaction in the native
antithrombin PBS (Figure 19A and 19B).
The results show that our hit molecules predicted to preferentially bind to activated
antithrombin rather than native antithrombin. However, they are also predicted to have
significant recognition capability for native antithrombin, which is very important for the
two-step induced-fit mechanism of antithrombin activation. The compounds with a 4carbon linker may be promising candidates for initial recognition of native antithrombin,
and also to activate fully antithrombin to inhibit factor Xa.
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Arg47

Arg129

Lys125

Figure 19. A. Predicted interaction of the short linker hit 6018 with native AT.

Arg47
Lys125

Figure 19. B. Predicted interaction of the extended linker hit 6411 with native AT.
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2.4.

Analysis of Predicted Binding Modes in the PBS of Activated Antithrombin

a. Linker types
In total, 16 types of linkers were explored that connect the bicyclic-unicyclic ring
systems in the core structure (Figure 13). Structural analysis of the 92 hit molecules in the
linker region showed the order of significance of the linkers as follows based on how many
molecules had the particular linker type.
35

32

Number of 'hits'

30
24

25
20

16

15

12

10
5

4

4

0
1

2

3

4

5

6

Number of atoms in linker
Figure 20. Histogram plot of the number of atoms in the linker for the 92 hits obtained
from virtual screening of a non-saccharide sulfated library
It is predicted that a 4- or 5- carbon linker with a double bond at either end of the
linker provides optimal geometries for these structures, allowing them to have strong
interactions with antithrombin. Of the 92 hits, 32 had an all-carbon 4-atom linker, while 24
had an all-carbon 5-atom linker (Figure 20). Of the 56 hits that had a 4- or 5-carbon linker,
34 had as (E) double bond configuration with a strong preference to be alpha to either the
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nitrogen atom or the phenyl ring (Figure 21) while 10 contained a (Z) double bond
configuration alpha to the phenyl ring system. The remaining 12 contained a fully
saturated linker.
The order of preference for the linkers is as follows:
-CH=CHCH2CH2CH2- (12) > -CH=CH2CH2CH2- (11) = -CH2CH2CH=CH- (11) >
-CH=CHCH2- (10) > -CONH- (10) > CH2CH2CH2CH2- (7) > -CH2CH2CH2CH=CH- (7) >
-CH2CH2CH2CH2CH2- (5) > -CH2CH2CH2CH2CH2CH2- (4) = -CH2- (4) > CH2CH=CHCH2- (3)> -CH2CH2CH2- (3) CH2CH=CH2 (3) > CH=CH- (2).

ISOQ_EXT_R_6345

ISOQ_EXT_R_6443
Figure 21. The hit structures with 4-carbon linkers showing double bond positions either
close to tetrahydroisoquinoline ring (6345) or phenyl ring system (6443).
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Of 25 molecules that have a double bond in the 4 carbon linker, 22 of them have
the double bond either close to isoquinoline ring or phenyl ring system (1-ene or 3-ene).
This indicates that the restricted rotation around the bulky ring system may help in
orientation of negatively charged functional groups in the binding site (Figure 21).
b. Importance of 3-carboxylate group
The 3-carboxylate in the tetrahydroisoquinoline ring may form a hydrogen bond
interaction with Lys125, provided that other sulfate groups in the tetrahydroisoquinoline
ring are appropriately positioned. Of 92 hit molecules, 69 (75%) of them has the COO−
group at position 3 of tetrahydroisoquinoline ring. The large percentage of hits containing
the 3-carboxylate indicates that substitution at this position with a negatively charged
group is of great significance.
The protein-ligand interaction analysis shows that out of 69 molecules with COO−
group, 43 of them are (R)-isomer and 26 are (S)-isomer. Though statistically the (R)-isomer
is preferred, (S)-isomers also have equally high GOLD scores (Table 1), indicating that
either isomer should be fine in that position, depending on other substitutions.
For example, the unique feature that facilitates the COO¯ interaction with Lys125
is the presence of 5-O-sulfate and 6-O-sulfate in the tetrahydroisoquinoline ring. In
particular, if the structure has 6, 7 or 6, 8 position sulfates, it is the 7-O-sulfate or 8-Osulfate that interacts with Lys125 and not the 3-carboxylate (Figure 22).
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R 129

R 47
K 125

A. ISOQ_R_6018

R 129

COO-

OSO3N

R 47

H
N

OSO3-

-O SO
3

OSO3-

O
-O SO
3

K 125

B. ISOQ_R_1059

Figure 22. ISOQ_R_6018 shows double hydrogen bond with Lys125 through the 5-Osulfate and 3- carboxylate, but ISOQ_R_1059 hydrogen bonds with Lys125 through the 8O-sulfate.
It is predicted that the presence of 5-O-sulfate and 6-O-sulfates in the ligand
structure helps Lys125 of antithrombin to form a double hydrogen bond, which makes the
ligand a better candidate for affinity (Figure 23). This distribution favors the molecule to
bind in such a way that facilitates the interaction of 3-carboxylate to Lys125. This is also
the reason why other compounds do not interact with Lys125. The presence of sulfate
groups only at the 6- and 8-, or 7-and 8- positions in the tetrahydroisoquinoline ring system
changes the face of the molecule in the opposite way such that the 8-O-sulfate interacts
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with Lys125 rather than the COO¯. There is a mutual competition between the 8-O-sulfate
group and the 3-COO¯ for Lys125, which is determined by the distribution of the rest of
the sulfate groups in the system.

Lys114
Lys125

Figure 23. Predicted binding geometry for hit ISOQ_R_6955 in the PBS of activated
antithrombin showing the influence of the 5- and 6-O-sulfates on the 3-carboxylate
interaction. The capped stick form of ‘hit’ 6955 is shown in green and sulfate groups in
SYBYL atom type. Activated antithrombin heparin binding amino acids are shown in
capped stick form in orange and the helices A, D and P in magenta. Note that the 3carboxylate and 5- and 6-O-sulfates are in the same direction, whereas the 8-O-sulfate
faces in the opposite direction.
c. Distribution of sulfate groups determines the binding mode
Overall, it is the distribution of sulfate groups in the core structure that make
hydrogen bond and ionic interactions with basic amino acids that determines whether a
molecule is going to bind and activate antithrombin or not. Although it looks simple, there
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is a significant preference for the presence of sulfate group in certain positions over others.
Structural information analysis of GOLD-docked dual filtered hit molecules reveals that
certain patterns of sulfate group substitution occur present more often than others. The
average number of sulfate groups in the tetrahydroisoquinoline and phenyl ring system that
is necessary is 2.
The frequency of charges at various positions of the core structure is shown in the
histogram (Figure 24), indicating the importance of charged functionalities at different
positions.
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Figure 24. Histogram plot of the frequency of charged groups (carboxylate and sulfate) in
various positions of the 92 hit compounds obtained from virtual screening of a nonsaccharide sulfated library.
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In Figure 25, the important positions are shown in color-filled ovals with their
respective percent sulfation among the 92 hit molecules. With respect to number and
distribution of negative charges, the majority of hits contained 4 to 6 negative charges.
Most interestingly, 48 of the 92 hits contained a 3,5,6-trisubstitutedtetrahydro
isoquinoline fragment (Figure 26) suggesting that sulfate groups at the 5- and 6-position of
the tetrahydro isoquinoline ring favorably contribute towards affinity .

71%
75%
86%

77%
Figure 25. Core structure showing the putative pharmacophore (colored ovals) for a series
of ISOQ analogs binding in the pentasaccharide binding site of activated antithrombin (L =
Linker size of 4- to 5-carbon length, R = –OSO3¯).

3,5,6-trisubstituted tetrahydroisoquinoline fragment
Figure 26. Key pharmacophore of the bicyclic ring system (referred as fragment I for
discussion purpose in the text) identified by docking to the PBS.
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The number of sulfate groups in the ring systems predicts the binding mode to be
one of two poses. The following example highlights the uniqueness of the distribution of
the sulfate groups and their impact in determining binding mode. Molecule ISOQ_R_277
is binding to activated antithrombin at PBS just exactly opposite direction compared to
molecule ISOQ_R_5183 (Figure 27).

R 129

R 47

K 125

A. ISOQ_R_5178
OSO3-

R 47

-O SO
3

O

R 129
OSO3-

N
H

N

OSO3-

K 125

-OOC

B. ISOQ_R_277

Figure 27. ISOQ _R_5178 and ISOQ_R_277 interactions with key basic amino acids
showing a complete reversal in its binding mode based on sulfate group distribution.
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The two molecules hit 5178 and hit 277 are essentially the same in its core structure
except in the distribution of sulfate groups. Hit 5183 has 5-, 7-, and 8-O-sulfate groups in
the tetrahydroisoquinoline ring system and the 2´-O-sulfate in phenyl ring system whereas
hit 277 has 2´-, 4´-, and 5´-O-sulfates in phenyl ring and 7-O-sulfate in
tetrahydroisoquinoline ring. This results in a complete predicted reversal of binding mode.
Furthermore, this kind of ‘flip’ is only observed when the tetrahydroisoquinoline
ring has one sulfate group and phenyl ring has more than 1 or 2, but if the number of
sulfate groups in the tetrahydroisoquinoline ring becomes 2 then the tetrahydroisoquinoline
stays in its preferred original binding mode even if the phenyl ring has 3 sulfate groups.
This prediction indicates that the number of sulfate group in the tetrahydroisoquinoline
ring predominantly determines the binding mode.
d. Predicted Binding Geometry of the Representative Hit Molecule
Hit molecule ISOQ_EXT_R_6955 represents one of the high-scoring favorable
molecules that have all of the above mentioned structural features. Hit 6955 contain a 4carbon linker with a double bond alpha to the phenyl ring. 3-carboxylate, 5-, 6-, and 8-Osulfates in the bicyclic ring, and 2′-, and 5′-O-sulfates in the phenyl ring system. Since this
molecule represents the common binding mode among most of the hit molecules, we will
discuss in detail its interactions with activated antithrombin at PBS (Figure 28 and Table
4).
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Hit 6955

Arg46

Arg47

Arg129
Lys114
Lys125

Arg132

Figure 28. Predicted binding geometry for hit ISOQ_R_6955 in the PBS of activated
antithrombin. The capped stick form of hit 6955 is shown in green and sulfate groups in
SYBYL atom type. Activated antithrombin heparin-binding amino acids are shown in
capped stick form in orange and the helices A, D and P in magenta. The interactions are
shown as dotted lines between ligand and amino acids.
Analysis of protein-ligand interaction predicted that the 3-COO− to interact with
Lys125, the 5-O-sulfate with Lys125 and Lys114, and the 8-O-sulfate with Arg46. The 6O-sulfate is predicted to interact with Arg46, Arg47 and/or Lys114. Its position is optimal
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in that it can anchor itself in the middle of Lys114, Arg46 and Arg47. It is interesting to
see that 79 of 92 hit molecules (86%) have a 6-O-sulfate, which in all cases interact with
Arg46, and Arg47/or Lys 114. This implies that this group may preferentially recognize a
specific feature in the protein. The 6-O-sulfate and other sulfate groups H-bond
specifically and exhibit a preferential binding mode. Analysis of sulfate group distribution
also reveals that with some preferable combinations it is possible to attain positive
interactions with critical basic amino acids (3-COO¯, 5-O-sulfate and 6-O-sulfate).
In the phenyl ring system, the 2′-O-sulfate is interacting with Arg129 and the 5′-Osulfate with Arg132, with additional interactions beyond those observed for the
pentasaccharide. A combination of 2′- and 5′-O-sulfates appears to be optimal on this end.
Table 4. Predicted interaction profile for hit molecule ISOQ_EXT_R_6955 at activated
antithrombin PBS.
Fragment

Ligand group

Amino acid

Distance in Å

3-Carboxylate

Lys125

3.5

5-O-sulfate

Lys125

3.3

Lys114

2.8

Lys114

3.0

Arg47

2.9

Arg46

2.6

8-O-sulfate

Arg46

3.1

Unicyclic ring

2′-O-sulfate

Arg129

3.0

(Phenyl)

5′-O-sulfate

Arg132

2.9

Bicyclic ring
(Tetrahydro
isoquinoline)

6-O-sulfate
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Structural and predicted binding geometry analysis of the following hit molecules
show that although they share many common features, differences in one or two important
positions can have a significant or insignificant effect on binding affinity in terms of
GOLD score (Figure 29 and 30).
Comparison of structures of ISOQ-EXT_R_6955, ISOQ-EXT_R_6411, ISOQEXT_R_6443 and ISOQ_EXT_6467 allows us to identify critical features needed for a
high GOLD score. For example, ISOQ-EXT_R_6443 is essentially the same as ISOQE6955 except for the absence of an 8-O-sulfate.

ISOQ_EXT_R_6443 (GOLD SCORE 127)

ISOQ_EXT_R_6955 (GOLD SCORE 132)

ISOQ_EXT_6467 (GOLD SCORE 110)

ISOQ_EXT_R_6411 (GOLD SCORE 120)

Figure 29. Representative structures showing the importance of sulfate and carboxylate
groups and their contribution to the modified GOLDScore. Important groups in the
reference hit 6955 are shown in the color filled ovals. Red icons indicate the absence of
that particular substitution in comparison to the reference structure.
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Arg46

Arg47

Arg129

Lys114
Lys125

Arg132

Hit molecules predicted binding geometries (aligned)

Hit 6955
(Score: 132)

Hit 6443
(Score: 127)

Hit 6411
(Score: 120)

Hit 6467
(Score: 110)

Figure 30. Predicted binding geometry of hit molecules in the activated antithrombin PBS.
Green crosses show the interactions of reference hit 6955. Red crosses show the missing
interactions in comparison to the reference compound responsible for reduction in the
GOLD score.
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The absence of the 3-carboxylate group makes a large difference in GOLD score of
ISOQ-EXT_6467 (127 to 110) and is well below the average GOLD score for a ‘hit’
candidate. (The average GOLD Score for hit compounds is 119). This indicates the
importance of 3-carboxylate group.
Hit 6443 is predicted to lose one interaction with Arg46 due to the absence of the
8-O-sulfate. Hit 6411, in addition to the 8-O-sulfate, does not have a 5′-O-sulfate group
which is predicted to result in the loss of another hydrogen bond interaction with Arg132.
This supports the idea of having 2 negatively charged groups in the phenyl ring system
preferably in the 2′- and 5′- positions. The 2′-O-sulfate is predicted to interact with Arg129
and the 5′-O-sulfate with Arg132.
The 3-ene double bond in the linker provides an additional structural feature that
restricts flexibility along the linker and places both 2′- and 5′-O-sulfate groups
appropriately for interactions with Arg129 and Arg132 respectively.
Interestingly, even though some of the interactions are missing in these molecules
in comparison to the reference structure (hit 6955), the presence of 5- and 6-O-sulfates and
the 4-carbon linker appears to play an important role in maintaining the same binding
geometry (Figure 30).
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Arg129

Arg46

Arg46/47
and Lys114

Arg132
Lys125

Lys114/125

Figure 31. Hit molecule ISOQ_EXT_R_6955 showing the critical pharmacophore. Ovals
in tan color represent the minimal requirements to recognize the PBS, whereas the ovals in
light green make additional interactions.
Based on the molecular docking predictions, we propose that the bicyclic ring
(tetrahydroisoquinoline) and the unicyclic ring (phenyl) connected by a 4-carbon linker
with a ‘trans’ double bond alpha to the phenyl ring, and 5-, 6- and 2′-O-sulfates form the
basis for recognition of activated antithrombin PBS in a consistent manner. Additional key
interactions are made by 8-O-sulfate (Arg46), 3-carboxylate (Lys125) and 5′-O-sulfate
(Arg132) groups for higher GOLD score, and presumably higher affinity (Figure 31).
e. Summary of structural features of most favorable hits
The representative hit ISOQ_EXT_R_6955 from the virtual screening study shows
the best fit in the PBS of activated antithrombin (Figure 28 and Table 4), but how well
does this molecule mimic the interactions of DEFGH, a heparin pentasaccharide? Figure
32 shows an overlay between pentasaccharide H5CRYS (Figure 9) and the hit 6955 from the
virtual screening study that contains the 3, 5, 6-trisubstituted tetrahydroisoquinoline
fragment shown above and a 2′-O-sulfate group in the unicyclic ring. The indicated pose of
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ISOQ_EXT_R_6955 was repeatedly predicted in triplicate docking experiments to be
within 2.5 Å RMSD (Table 2).
The figure shows the predicted striking similarities in the location of 4 negative
charges: 1) the 2′-O-sulfate group of ISOQ_EXT_R_6955 overlaps with the D-ring 6-Osulfate group of H5CRYS, 2) the 3-carboxylate overlaps with the E-ring carboxylate of the
H5CRYS, 3) the 5-O-sulfate overlaps with the critical unique F-ring 3-O-sulfate of the
H5CRYS and 4) the 6-O-sulfate overlaps with the G-ring carboxylate group of the H5CRYS.

3'
4'
-

O3SO 5'

6'

OSO32'
3

1
2

4

1
2

N

OOC 3

-

4

Arg46

OSO38
7
6 OSO35
OSO3-

E

D

G

F

H

Arg47
Arg129
Lys125

Lys114

Arg132
Figure 32. Overlay of heparin pentasaccharide H5 (gray), obtained from the crystal
structure (PDB: 1TB6) and the consistently-predicted docking pose of hit
ISOQ_EXT_R_6955 (green, structure shown in in-lay) from the virtual screening study of
sulfated non-saccharide molecules. Overlying negative charges (sulfate and carboxylate
groups) are circled. The critical PBS residues Lys114, Lys125 and Arg129 interact with
the 6-O-sulfate, 5-O-sulfate and 2′-O-sulfate groups of ISOQ_EXT_R_6955, respectively,
which in turn overlay with the G-ring carboxylate, F-ring N-sulfate and D-ring 6-O-sulfate
groups of the H5 sequence. In addition, the 3-carboxylate of ISOQ_EXT_R_6955 and the
E-ring carboxylate of H5 overlap and interact with Lys125. The 5′-O-sulfate makes an
additional interaction with Arg132.
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These charges are predicted to interact with the critically important positively charged triad
(Lys114, Lys125 and Arg129) which is located in the pentasaccharide-binding site (PBS)
in antithrombin (AT). Additionally, the 5′-O-sulfate group of ISOQ_EXT_R_6955 is
predicted to interact with the extended heparin-binding site residue Arg132. Thus, the
bicyclic ring is predicted to bind in the center of the PBS, and the unicyclic ring at the
interface of the PBS and EHBS.
It is important to note that the 6-O-sulfate group in ISOQ_EXT_R_6955 overlaps
with a carboxylate group of H5CRYS. Since the 6-O-sulfate group is well-placed in the
middle of Lys114, Arg46 and Arg47, and the sulfate group contains three potential
interaction points, it is predicted to simultaneously interact with Lys114 (Helix P) and the
N-terminal residues Arg46 and Arg47 (Helix A) (Figure 27 and table 6). At the same time,
the G ring carboxylate of H5CRYS appears to interact only with Arg46 (hydrogen bond and
ionic interaction).
Another interesting result of our virtual screening study is the dependence of the
overlap of structures shown in Figure 33 with linker length for the series of hits that
contain fragment I and the 2´-O-sulfate group of the unicyclic ring.
Figure 34 reveals that, irrespective of the exact nature of the linker, the docking
pose orients the interacting negative charges in an identical manner. For example,
ISOQ_EXT_R_6748 with a 5-carbon linker containing a (Z)-double bond has a predicted
binding mode similar to ISOQ_EXT_R_6687 that contains a fully saturated linker. This
binding mode does not depend on the configuration of the carboxylate group (R- and Sisomers dock similarly) or even the absence of this group (not shown). This prediction
88

supports our conclusion that while 5- and 6-O-sulfates are necessary for favorable binding
mode in PBS, a 4- to 5- carbon linker is predicted to be optimal for placing the unicyclic
ring to reach for interaction with Arg129.
Table 5. Summary of structural features of hit molecules
Fragment I

Number
of ‘hits’

GOLD Scores

Percentage with
4 or 5 carbon
linkers

37

104-132

76%

OSO35

2'
3'

3
4

2

2

6'

4'

-

5'

1

1

OOC

8
7

N

3

4

5

6
OSO3-

ISOQ_EXT_R_6955 (Green)

ISOQ_EXT_R_6170 (Cyan)

ISOQ_EXT_R_6687 (Gray)

ISOQ_EXT_R_6988 (Black)

Figure 33. The hit structures with fragment I, but with variation in the linker
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OSO3-

Arg46
Arg129
Arg47

Lys125

Lys114

Arg132

Figure 34. Overlay of different docked poses of hits cotaining core fragment I and 2'substituted unicyclic ring. Note the striking similarity of ortientation of the bicyclic ring
and circled negative charges. Green capped stick: ISOQ_EXT_R_6955; Cyan capped
stick: ISOQ_EXT_R_6170; Gray capped stick: ISOQ_EXT_R_6687; Black capped stick:
ISOQ_EXT_R_6988.
2.5.

Initial Biochemical Validation of Modeling Results
The molecular modeling results presented in the above sections lead to several

hypotheses, as may be apparent from the discussion following results. Of special
importance are three hypotheses. The modeling results suggest 1) an optimal length of the
4 to 5 atom linker; 2) 2′,5′-disulfated unicyclic ring; and 3) 3,5,6-trisubstituted bicyclic ring
are to be important. The hypotheses form the basis of synthetic work currently in progress
in the Desai laboratory. The synthesis of highly sulfated molecules is challenging as
demonstrated by previous work on such molecules in the laboratory.209 To date, no
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molecule with all three features has been synthesized. Yet, the laboratory has just
synthesized and tested one molecule that may serve as initial test of molecular modeling
experiments.

Figure 35. Structure of synthesized molecule 67A2L25.

Arg46

Arg47
Lys114
Arg129

Lys125

Figure 36. The predicted binding modes for the synthesized molecule 67A2L25 in
triplicate docking experiment (2 top ranked solutions from each experiment). The solid
black lines show the possible interactions between the ligand and the protein. Maximum
GOLDScore is 97.2.
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Potential activator 67A2L25 (Figure 35) was synthesized (by Mr. Al-Horani) and
evaluated (by Dr. Liang) using the standard antithrombin activation protocol developed by
the laboratory. Activator 67A2L25 has a 6,7-disulfated bicyclic ring (instead of 5,6disubstitution), a two carbon linker (instead of 4 or 5 carbon linker); and a 2,5disubstituted unicyclic ring (as desired).
Biochemical analysis of 67A2L25 shows an antithrombin activation potential in the
region of 50- to 100-fold (the high variance is because of the very high salt content as
impurity in the sample). The activation potential of 67A2L25 is much less than full
antithrombin activation (300-fold), but significantly more than 8 – 30-fold activation
achieved with previous designs.134,135,209 The antithrombin affinity was found to be
between 1 and 5 μM at pH 7.4. This is significantly higher than affinities of all previous
designs (50 to 500 μM),171,212,214 though still less than most potent saccharide-based
activators (50 to 100 nM).
Since the synthesized molecule was not originally present in the virtual library, this
molecule was docked using the same docking parameters. Modeling results for the
synthesized molecule shows that the GOLD score for 67A2L25 is 97.2, which is lower
than the scores for the hit molecules identified in the virtual library screening, and the
binding modes are also divergent in triplicate docking experiments.
Several conclusions may be derived based on this single data point. 1) The
activation is not full (50-100 fold in comparison to 300-fold) for compound 67A2L25
probably because of the absence of optimal structural features, as predicted by GOLD
modeling; 2) the activation is much better than that realized with previous designs
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probably because of the slightly longer linker and/or 2′,5′-disulfation of the unicyclic ring;
3) the antithrombin affinity of 67A2L25 is found to be higher perhaps because of more
optimal features (slightly longer linker and/or 2,5-disulfation of unicyclic ring) than those
present in previous designs; and 4) the antithrombin affinity of 67A2L25 is not as great as
the most optimal saccharide activators because all features suggested by the docking
experiments have not been introduced. Overall, the antithrombin binding and activation
results obtained with 67A2L25 are consistent with the GOLD-based molecular modeling
results obtained and provide stronger impetus to synthesize and test the ‘high-affinity,
high-specificity’ molecules identified in this work.
2.6.

Experimental Section

2.6.1. Software/Hardware
SYBYL 7.2 (Tripos Associates, St. Louis, MO) was used for molecular
visualization, for minimization, and for adding hydrogens to protein structures from the
Protein Data Bank. All modeling was performed on MIPS R16K or R14K IRIX 6.5-based
SGI Tezro and Fuel graphical workstations. GOLD version 3.0 was used for docking
experiments. Combinatorial tetrahydroisoquinoline bicyclic-unicyclic small molecule
structures were built using LEGION, a structure building module that creates all possible
structures in compliance with the given input limits for a core structure. Then the structures
were converted into 3D form by the program CONCORD and checked for atom types in an
automated manner using in-house SPL (SYBYL Programming Language) scripts.
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2.6.2. Energy Minimizations
Energy minimization of modeled structures was performed to optimize the
geometric conformation of small molecules in the library and the protein antithrombin.
Except where stated, energy minimization was performed using the Tripos Force Field
with Gasteiger-Hückel charges, a fixed dielectric constant of 80, and a non-bonded cutoff
radius of 8Å. Minimization was carried out for a maximum of 5000 iterations subject to a
termination gradient of 0.05 kcal/(mol-Å) for protein whereas for small molecules 10000
iterations subject to a termination gradient of 0.01 kcal/(mol-Å).
2.6.3. Protein Coordinates
The coordinates for the activated form of AT were extracted from the crystal
structure of the ternary AT–pentasaccharide–thrombin complex (PDB entry 1TB6).
Hydrogen atoms were added in SYBYL 7.2 and the structure was minimized with fixed
heavy-atom coordinates using the Tripos force field for 1000 iterations subject to a
termination gradient of 0.05 kcal / (mol-Å). Single-point correction was made on AT
(1TB6) at Lys133 side chain which is incomplete in its original crystal structure
(AT_K133). The side-chain of the corrected residue was optimized through energy–
minimization in which the all other side chains were held rigid. Native antithrombin
coordinates were extracted from PDB structure 2ANT.
2.6.4. Coordinates for ISOQ Virtual Library
The coordinates for the virtual library of 24576 compounds based on the
tetrahydroisoquinoline scaffold were generated with a series of SPL scripts from a core
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structure with variable substitutions using LEGION and CONCORD. Atom type checks
and appropriate changes were made by an in–house SPL script.109 The structures were then
minimized using the Tripos force field for 10000 iterations subject to a termination
gradient of 0.01 kcal / (mol-Å) in an automated manner.
2.6.5. Docking Protocol
Docking of the virtual library onto the activated and native form of antithrombin
was performed with GOLD v.3.0. The Pentasaccharide Binding Site (PBS) in activated
antithrombin is predefined as all atoms within 16 Å from the Cζ atom of Phe121 in the D
helix. This definition of the binding site covers all important known heparin binding
residues including Lys11, Arg13, Arg46, Arg47, Trp49, Lys114, Phe121, Lys125, Arg129,
and Arg132.
The Extended Heparin Binding Site (EHBS) in activated antithrombin is predefined
as all atoms within 14 Å from Cα of Lys133 in the D helix which includes Lys125, Arg129,
Arg132, Lys133, Lys136, and Lys139.
The binding site in native antithrombin is predefined as all atoms within 19 Å from
the terminal N atom of Lys125 in the D helix which includes Lys11, Arg13, Arg46, Arg47,
Trp49, Lys114, Phe121, Lys125, Arg129, and Arg132.
GOLD is a “soft docking” method that implicitly handles local protein flexibility
by allowing a small degree of interpenetration, or van der Waals overlap, of ligand and
protein atoms. GOLD also optimizes the positions of hydrogen-bond donating atoms on
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Ser, Thr, Tyr and Lys residues as part of the docking process. Unless specified otherwise,
default parameters were employed during the GOLD docking runs.
When docking the virtual combinatorial library, a two-step docking protocol was
utilized. The first step consisted of docking all structures in the library using 10000 GA
iterations (7×8 speed up) and GOLD score evaluation of only the top-ranked solution. In
this step, most promising candidates were identified (structures with GOLD Score of 100
and above, GOLD Score for DEF is 115 and for DEFGH is 140). The second step
consisted of docking of hits obtained from the first step in triplicate using no speed-up
and a genetic algorithmic search with 100000 iterations for each of 10 runs to ensure
reproducibility and to reduce false positives. In this search, GOLD starts with a population
of 100 arbitrarily docked ligand orientations, evaluates them using a scoring function (the
GA “fitness” function) and improves their average “fitness” by an iterative optimization
procedure that is biased toward high scores. As the initial population is selected at random,
several such GA runs are required to more reliably predict correct bound conformations. In
this study 10 GA runs were performed with the GOLD score as the “fitness” function.
Collectively, these 10 GA runs will be referred to as one docking experiment. In addition,
to enhance speed, the GA was set to preterminate if at any point during the docking run the
top two ranked solutions were within 2.5 Å RMSD. The top-ranked solution of each
docking experiment was considered for further analysis.
Docking was driven by the GOLD scoring function. Although this scoring function
correlates with the observed free energy of binding, a modified form of the scoring
function has been found to be more reliable for this purpose. This modified GOLDScore,
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which utilizes hydrogen-bonding and van der Waals interactions (Eq.1) was used to rank
the final docked solutions.
1.375

. 2

HBext and VDWext are the “external” (non-bonded interactions taking place between the
ligand and receptor) hydrogen bonding and van der Waals terms, respectively. Unless
otherwise noted, the terms ‘GOLD Score’ and ‘modified GOLDScore’ in this work both
refer to Equation 2.

Table 2. RMSD data for hit molecules which passed the affinity and specificity filter
convergence cut off value 2.5 Å in triplicate.
SL.
NO.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

COMPOUND

ISOQ_1903
ISOQ_2561
ISOQ_6435
ISOQ_2096
ISOQ_5809
ISOQ_6162
ISOQ_R_1875
ISOQ_R_2106
ISOQ_R_5769
ISOQ_R_6018
ISOQ_R_6053
ISOQ_R_6408
ISOQ_R_1960
ISOQ_R_6082
ISOQ_R_1059
ISOQ_R_277
ISOQ_R_5183
ISOQ_R_5218
ISOQ_R_5325
ISOQ_S_1873

DOCK 1
RMSD

DOCK 2
RMSD

DOCK 3
RMSD

RMSD
1 to 2

RMSD
2 to 3

RMSD
1 to 3

1.4
2.4
0.9
2.0
1.6
1.1
0.9
1.8
1.3
0.5
0.2
1.5
0.5
1.8
1.1
0.4
2.3
1.3
1.4
1.4

1.5
2.2
1.4
1.3
2.3
0.8
2.4
1.4
1.4
0.5
0.7
1.1
1.4
1.6
0.5
1.1
0.2
0.7
1.0
1.2

1.2
1.8
0.8
0.5
1.7
1.4
1.0
1.1
1.8
0.5
2.3
2.2
1.5
0.8
0.6
0.3
0.9
2.3
1.8
1.2

1.5
2.2
1.5
1.5
1.3
1.3
1.7
1.8
1.5
0.8
1.0
1.8
1.1
1.4
0.8
1.1
1.1
1.0
1.7
1.7

1.8
2.4
1.1
1.5
1.6
1.3
1.2
1.3
1.1
1.1
1.2
1.2
1.8
1.4
1.0
1.1
1.0
0.9
2.2
1.2

1.6
0.9
1.1
0.7
1.8
1.3
1.7
1.7
1.5
1.1
1.2
1.8
1.6
1.2
0.9
0.9
0.9
1.1
1.8
1.5
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21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63

ISOQ_S_2072
ISOQ_S_4255
ISOQ_S_5963
ISOQ_S_6153
ISOQ_S_6159
ISOQ_S_6330
ISOQ_S_6463
ISOQ_S_6623
ISOQ_S_6652
ISOQ_S_6960'
ISOQ_S_7547
ISOQ_S_7832
ISOQ_EXT_S_1229
ISOQ_EXT_S_1243
ISOQ_EXT_S_6185
ISOQ_EXT_S_6234
ISOQ_EXT_S_6236
ISOQ_EXT_S_6410
ISOQ_EXT_S_6411
ISOQ_EXT_S_6448
ISOQ_EXT_S_6462
ISOQ_EXT_S_6815
ISOQ_EXT_S_6971
ISOQ_EXT_S_6987
ISOQ_EXT_S_6988
ISOQ-EXT_5142
ISOQ-EXT_6294
ISOQ-EXT_6550
ISOQ-EXT_3201
ISOQ-EXT_6225
ISOQ-EXT_6467
ISOQ-EXT_979
ISOQ-EXT_2850
ISOQ-EXT_2866
ISOQ-EXT_3906
ISOQ-EXT_6402
ISOQ-EXT_6434
ISOQ-EXT_706
ISOQ-EXT_7938
ISOQ-EXT_6532
ISOQ-EXT_855
ISOQ-EXT_7064
ISOQ-EXT_R_3182

0.2
1.4
0.8
2.4
1.6
0.8
1.7
0.9
1.6
2.4
0.9
0.8
1.1
0.7
0.6
1.6
2.1
2.3
1.5
0.7
1.5
2.0
1.4
2.0
0.8
1.6
1.2
0.5
2.2
1.2
1.1
1.4
1.2
2.2
1.4
2.0
0.8
1.0
2.3
0.6
1.7
2.1
1.3

1.9
0.5
1.0
1.3
0.6
1.7
1.9
1.0
1.3
2.2
1.6
0.7
0.3
1.3
1.1
2.0
1.0
1.5
0.5
0.6
1.4
1.6
0.9
2.3
1.7
1.3
0.4
1.8
0.5
0.9
1.7
1.0
1.6
2.4
1.9
1.1
2.4
0.6
1.2
2.3
2.5
2.2
0.9
98

0.7
1.3
0.6
2.3
1.0
1.0
0.9
1.0
0.6
2.4
0.7
1.4
1.1
0.2
0.7
2.5
1.1
2.0
1.4
1.2
1.1
1.3
1.7
0.6
2.4
1.8
0.8
1.3
1.0
0.4
2.3
1.2
0.9
1.1
1.5
2.1
1.4
1.2
1.3
2.5
0.5
1.6
2.1

1.9
1.5
1.0
2.4
1.0
1.3
1.6
1.4
1.8
2.4
1.1
0.9
1.0
1.3
1.2
1.4
1.7
2.1
1.1
1.7
0.9
1.8
1.7
1.7
1.5
1.1
0.9
1.2
2.2
1.3
1.5
1.9
1.8
2.2
1.9
1.2
1.4
1.4
1.4
1.2
1.5
2.4
2.5

1.6
1.3
0.9
1.1
1.2
0.9
1.3
0.6
1.5
2.4
1.5
1.2
1.0
0.7
1.1
1.5
1.7
1.8
1.2
1.4
2.0
1.4
1.1
1.1
1.6
1.5
1.3
1.5
1.8
1.6
1.4
1.8
1.6
1.8
2.0
1.1
1.7
1.4
1.8
1.6
1.5
2.4
1.3

1.5
1.2
1.0
2.5
1.0
1.1
1.4
1.4
1.7
1.2
1.7
1.1
1.0
1.3
1.4
1.5
1.1
1.6
1.2
2.1
1.9
1.8
1.6
1.6
1.9
1.0
0.9
1.8
1.5
1.0
1.4
1.6
1.7
1.4
1.1
0.9
1.9
1.0
1.7
1.4
1.0
1.7
2.4

64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92

ISOQ-EXT_R_6318
ISOQ-EXT_R_6542
ISOQ-EXT_R_6217
ISOQ-EXT_R_6281
ISOQ-EXT_R_6297
ISOQ-EXT_R_6345
ISOQ-EXT_R_6409
ISOQ-EXT_R_6473
ISOQ-EXT_R_6857
ISOQ-EXT_R_6921
ISOQ-EXT_R_2861
ISOQ-EXT_R_6253
ISOQ-EXT_R_6411
ISOQ-EXT_R_6443
ISOQ-EXT_R_6555
ISOQ-EXT_R_6955
ISOQ-EXT_R_731
ISOQ-EXT_R_6170
ISOQ-EXT_R_6474
ISOQ-EXT_R_6538
ISOQ-EXT_R_2956
ISOQ-EXT_R_6444
ISOQ-EXT_R_6732
ISOQ-EXT_R_6988
ISOQ-EXT_R_2591
ISOQ-EXT_R_3279
ISOQ-EXT_R_6687
ISOQ-EXT_R_3408
ISOQ-EXT_R_6224

1.4
0.6
1.3
0.9
0.6
0.9
2.4
2.1
2.4
1.1
1.8
2.5
0.6
1.1
1.6
1.2
0.7
1.7
1.5
1.4
1.8
1.8
2.2
1.3
1.3
1.6
1.9
1.8
1.9

1.6
0.9
1.8
0.9
0.4
1.5
2.3
0.6
2.5
2.3
0.9
0.9
1.2
1.1
1.1
1.5
1.5
1.5
1.5
1.4
2.3
2.2
1.6
2.4
2.0
2.3
0.6
1.7
1.3
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1.5
1.3
2.3
2.3
1.1
1.0
2.0
0.7
2.2
1.8
2.2
2.2
0.4
0.4
1.6
1.2
1.2
1.2
1.3
0.9
2.2
2.2
2.2
1.6
0.8
1.7
2.1
2.5
1.7

2.0
1.4
1.7
0.8
1.4
1.5
0.7
1.6
1.5
1.5
1.8
2.4
1.0
0.9
0.8
1.1
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CHAPTER 3
DESIGNING SPECIFIC THROMBIN EXOSITE-II MODULATORS

3.1.

Introduction
As described in chapter 1, heparin is a complex carbohydrate biopolymer made of

linear polysaccharides of varying chain length and is composed of uronic acid and
glucosamine residues.113 Although heparin is a commonly used anticoagulant it suffers
from serious side effects such as excessive bleeding complications, heparin induced
thrombocytopenia, and significant intra- and inter-patient dose response variability.173,174
Most of the side effect complications arise primarily from its structural complexity
and its interaction with numerous proteins other than coagulation proteins factor Xa (fXa),
thrombin, and antithrombin (Table 6). Implicitly these diverse roles must arise from an
optimal combination of specificity and affinity. However with the exception of a few
cases, the specificity of heparin interactions has been poorly understood and not explored
in detail.
A major reason for the limited understanding of heparin–protein interactions is due
to the phenomenal structural diversity of heparin. Structural diversity of heparin is a result
of the complex, highly anionic polysaccharides composed of alternating 1→4-linked
glucosamine and uronic acid residues, which are variously modified through sulfation,
acetylation and epimerization.172 These modifications can produce 48 different
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disaccharide building blocks, of which 23 have been found to date (Figures 37 and 38).220
In addition, the iduronic acid residue (IdoAp) can exist in multiple conformations,
especially 1C4 and 2SO for internal locations that can inter-convert relatively easily (Figure
39).132,221 As a result, the combination of structural and conformational variability
generates millions of sequences, of which few are expected to specifically recognize a
target protein.
Specificity in heparin-protein interaction is a function of both the target protein and
the heparin sequence that binds the protein. Capila, I and Linhardt R. J. have reviewed the
interactions of heparin with many different proteins (Table 6).115

Table 6. Characteristics of selected list of GAG binding proteins. Adapted from Capila, I.;
Linhardt, R. J. Heparin–Protein Interactions. Angew. Chem. Int. Ed. 2002, 41, 390-412.
Heparinbinding protein
Antithrombin
Thrombin*
FGF-1

FGF-2
PF-4
IL-8
SDF-1α
HIV-1 gp120
HSV gB and gC

Physiological/
pathological role
Coagulation cascade
Coagulation cascade
Cell proliferation,
differentiation,
morphogenesis and
angiogenesis
As FGF-1
Inflammation and
wound healing
Pro-inflammatory
cytokine
Pro-inflammatory
mediator
Viral entry inhibition
Viral entry inhibition

Sequence features#

~20nM
7µM
nM

Oligosaccharide
size
5-mer
8-mer
4-mer to 6-mer

nM
nM

4-mer to 6-mer
12-mer

IdoA2S-GlcNS
HS/LS/IS

~6µM

18-mer to 20-mer

HS/LS/IS

~20nM

12-mer to 14-mer

HS

0.3µM
−

10-mer
−

HS
−

KD

GlcNS3S6S
HS
IdoA2S-GlcNS6S

*Data is obtained from Huntington et al. J Biol. Chem. 2005, 280, 2745-2749. #HS: high sulfation, IS:
intermediate sulfation, LS: Low sulfation
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HS2

HS8

HS3

HS3a

HS9

HS9a

HS6

HS6a

HS12

HS1

Figure 37. The glucuronic acid-containing disaccharide subunits known to be present in
heparin/heparan sulfate. Groups in magenta show the difference in sulfation pattern
between the pairs (the names of the disaccharides containing a 2-O-sulfate glucuronic acid
residue end with the letter ‘a’). Adapted from Esko, J. D.; Selleck, S. B. Order out of
chaos: Assembly of ligand binding sites in heparan sulfate. Annu. Rev. Biochem. 2002, 71,
435-471.
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HS14 (1C4 and 2SO)

HS14a (1C4 and 2SO)

HS20 (1C4 and 2SO)

HS20a (1C4 and 2SO)

HS15 (1C4 and 2SO)

HS15a (1C4 and 2SO)

HS21a (1C4 and 2SO)

HS21 (1C4 and 2SO)

HS18 (1C4 and 2SO)

HS18a (1C4 and 2SO)

HS16a (1C4 and 2SO)

HS24 (1C4 and 2SO)
Figure
38.
The
iduronic
acid-containing
disaccharide subunits known to be present in
heparin/heparan sulfate. Groups in magenta show
the difference in sulfation pattern between the pairs
(the names of the disaccharides containing a 2-Osulfate iduronic acid residue end with the letter ‘a’).

HS22a (1C4 and 2SO)

Adapted from Esko, J. D.; Selleck, S. B. Order out of chaos: Assembly of ligand binding sites in heparan sulfate. Annu. Rev. Biochem.
2002, 71, 435-471.

103

1

C4

4

O

C1

S2

2

SO

Figure 39. Iduronic acid conformations (1C4 and 2SO predominantly exist in GAGs)
On the protein front, Cardin and Weintraub were the first to study the general
structural requirements for GAG-protein interactions.222 They have demonstrated that the
heparin binding domain in the protein has defined binding motifs of linear consensus
sequences with specific repeat pattern. Others have suggested a spatial distance
relationship to be important for heparin binding.223,224
Arginine and lysine residues in the protein surfaces dominate heparin-binding sites
and are known to be critical in heparin binding. It is also known that not all arginine and
lysine interactions with sulfate and carboxylate groups of heparin are identical. Arginine
has been shown to bind 2.5 times more tightly than lysine due to the strong bidendate
interaction of the guanidino group with sulfate and carboxylate groups.225 Even though
heparin–protein interactions are known to be primarily charge-based interactions, the
degree of ionic contribution varies significantly among heparin-binding proteins. In the
case of antithrombin and basic fibroblast growth factor, the ionic binding energy
contribution is ~40% and 30% respectively, but with thrombin, it is ~80%.206,226,227
Although the importance of individual amino acids in recognizing heparin
fragments has been studied in many proteins, the optimal 3D orientation that generates
high specificity and affinity remains unclear. Considering the complexity of heparin
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structure and its diverse physiological functions, molecular modeling and computational
docking approaches represent a powerful means to address the structural complexity of
heparin and exploring the issue of specificity and binding affinity of heparin–protein
interactions.
In the present work, we have used molecular modeling approaches to explore the
nature of the heparin binding site in antithrombin and thrombin with a special focus on
understanding specificity/non-specificity. Understanding the features that are important for
specificity in this complex system both in protein and GAGs, extracting the hidden
information and decoding them will enable us to design new therapeutic agents possibly
without the above-mentioned side effects and limitations associated with GAG-based
anticoagulants.
3.2.

Rationale
The interaction of heparin with antithrombin and thrombin is the basis for

anticoagulation therapy. On one hand, the interaction of heparin with antithrombin is a
known example of specific interaction. A specific five-residue present in heparin, called
pentasaccharide DEFGH sequence (Figure 40), mediates the interaction with antithrombin.
In fact, the absence of this sequence makes the heparin chain incapable of binding to
antithrombin under physiological conditions. The importance of individual amino acids
interacting with this sequence-specific pentasaccharide and the role of each residue in the
pentasaccharide responsible for recognition and affinity to antithrombin has been
extensively studied.166,167,206,207,209
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On the other hand, heparin interaction with thrombin is considered to be a nonspecific interaction. Equilibrium binding studies of heparin binding to thrombin by Olson
et al. clearly showed that heparin interaction is a non-specific electrostatic interaction.227
This is also supported by the crystal structure study of thrombin bound to heparin
octasaccharide.228 In the crystal structure, heparin octasaccharide has two different
orientations (binding mode) in the heparin binding site also known as thrombin exosite-II
(Figure 44).
In antithrombin, there are three important amino acids involved in heparin
pentasaccharide binding: Lys114, Lys125 and Arg129. In thrombin, there are at least
seven basic amino acids predicted to be involved in heparin octasaccharide binding:
Arg93, Arg101, Arg126, Arg165, Arg233, Lys236 and Lys240. In general, one would
expect less specificity with fewer interacting points in the target protein, or alternatively
greater specificity with more interacting points. However, what has been observed is the
reverse: whereas thrombin with more Lys and Arg shows non-specific interaction,
antithrombin with fewer Lys and Arg makes specific interaction. The molecular basis
responsible for the origin of this specificity/non-specificity is not clear. We reasoned that
molecular modeling techniques may be used to analyze this issue.
3.3.

Antithrombin-Heparin: Specific Interaction
As mentioned earlier, a specific five-residue GAG sequence present in heparin,

called pentasaccharide DEFGH (Figure 40), mediates the interaction with antithrombin.
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Absence of this sequence renders the heparin chain incapable of binding to antithrombin
under physiological conditions.

D

E

F

G

H

Figure 40. Structure of a specific five-residue heparin pentasaccharide DEFGH. Groups in
magenta are known to be important for specificity.
Heparin chains containing the DEFGH sequence are referred to as high-affinity
heparin (HAH) chains. Pentasaccharide DEFGH binds to antithrombin with ~50 nM
affinity under physiological conditions. This binding affinity accounts for ~95% of the free
energy of binding of the full-length polymer. This binding energy is contributed due to the
interactions of 6-O-sulfate group of D ring, 6-COO¯ group of ring E, 2-O-sulfate and 3-Osulfate of F ring, and 2-N-sulfate of ring H in the pentasaccharide binding site (PBS).217 Of
these, the rare 3-O-sulfate group of the central glucosamine F plays the key role without
which the affinity of the sequence is lost.217,229 This sequence-specific interaction of
DEFGH with antithrombin serves as a model for specificity. (Figure 41)
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PBS
Helix A

Arg46
G

E
D

Arg47

F
Lys114

Arg129

H

Helix P

Lys125

Lys133

Lys136

Helix D
Arg132

EHBS
Figure 41. A close-up view of the structure of the heparin-binding sites in antithrombin
(PBS and EHBS). The structure of co-complex was obtained from PDB entry 1AZX.
Pentasaccharide DEFGH is shown in ball-and-stick representation. Helices D, P and A (Cterminal end) form the heparin-binding site. Arg46, Arg47, Lys114, Lys125 and Arg129
form the pentasaccharide binding site (PBS), while Arg132, Lys133 and Lys136 form the
extended heparin-binding site (EHBS).
It appears that DEFGH specificity in antithrombin is a result of its multiple
interactions with the Lys and Arg residues of the HBS. These include residues of the Nterminus, helix A, and helix D. Of these, Lys114, Lys125 and Arg129 of helix D
contribute ~50%, ~25-33% and ~28-35% of the total binding energy, respectively, and
form a coordinated network of interactions.166-170,230 The domain formed by these three
residues is called the pentasaccharide-binding site (PBS, Figure 41). The PBS also contains
108

other residues that play an important role in heparin binding, including Lys11, Arg13,
Arg24, Arg47, Trp47, and Phe122.231-233 A full-length heparin binds to PBS in
antithrombin and to an extended region formed by residues Arg132, Lys133 and Lys136 at
the C-terminal end of helix D. This extended region is termed the extended heparin binding
site (EHBS, Figure 41). Although the detailed architecture responsible for specificity in
antithrombin remains unclear, it can be concluded that DEFGH interaction with
antithrombin is specific and well-defined.
3.3.1. Molecular Modeling of Antithrombin-Heparin Specific Interaction
Previous computational attempts to model heparin pentasaccharide binding site on
antithrombin using molecular dynamics and docking by both Grootenhuis and van
Boeckel234 and Bitomsky and Wade119 resulted in geometries that are significantly different
from the co-crystal structure. In contrast, with a robust docking protocol based on dualfilter strategy the Desai lab predicted the high-specificity GAG sequences that bind
antithrombin with remarkable accuracy.109 The docking protocol using GOLD program
predicted the binding geometry of natural pentasaccharide sequence DEFGH with an
“average GAG backbone” conformation to within 2.5 Å (Figure 42).
The docking results suggested that the sulfate groups organized in a specific threedimensional orientation to afford the specificity of interaction, a conclusion proposed
earlier on the basis of a large number of structure-activity studies.109
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X-ray
GOLD
D

F

E

2SF

6AE
3SF

H

K114

hA

6SD
R129

G

K125

hP

hD
Figure 42. Comparison of GOLD predicted binding geometry of natural pentasaccharide
H5 having ‘average backbone’ with that of H5CRYS determined in the crystal structure. An
overlay of 6 solutions from three independent docking runs shows high consistency in the
predicted binding geometry, which matches the crystal structure geometry with an RMSD
less than 2.5 Å. The structure in green is the crystal structure geometry (DEFGH with an
additional residue in the non-reducing end), while those in atom-type color (red, yellow,
grey and blue) are 6 docking solutions. Note the identical orientation of key groups, 2- and
3-OSO3- of residue F (2SF and 3SF), 6-COO- of residue E (6AE) and 6-OSO3- of residue D
(6SD). Helices A, D and P of antithrombin (in ribbon diagram) are indicated by hA, hD and
hP, while D, E, F, G, and H labels correspond to residues of the pentasaccharide. K114,
K125 and R129 are shown in ball-and-stick representation. Reproduced from Raghuraman,
A.; Mosier, P.D.; Desai, U. R. Finding a Needle in a Haystack: Development of a Virtual
Screening Method for Identifying High Specificity Heparin/Heparan Sulfate Sequence(s). J
Med Chem. 2006, 49, 3553-3562.
Raghuraman et al. also docked pentasaccharide variants to antithrombin and found
a significant correlation between GOLD scores and binding affinity (slope of 4.2 GOLD
score units per kcal/mol and an intercept of 78.9 GOLD score units). The result indicated
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that self-consistency of docking geometries is sensitive to sulfate group distribution and
pentasaccharide topology. The dual-filter strategy rapidly sorted a combinatorial virtual
library of nearly 7,000 heparin hexasaccharides into specific and non-specific sequences,∗
thus suggesting its potential use for identifying ‘needle(s) in a haystack’.
While this work by Raghuraman et al. has added a significant contribution in the
understanding of the specificity in terms of the GAG-ligand, the counterpart, the protein
architecture responsible for such a defined specificity in antithrombin, has not been
addressed. Though there are many papers published in detailing the importance of amino
acids in heparin binding site, the detail architectural details responsible for specificity
remains unclear. However, in one case, an observation was made in reference to the
appropriate position of the Arg129 side chain in activated antithrombin due to the H-bond
effect of primarily Glu414 and Thr44 to keep the pentasaccharide anchored to the activated
state of the inhibitor.169
3.4.

Thrombin-Heparin: Specific or Non-specific Interaction?
Thrombin is a serine proteinase enzyme and has four important binding sites: the

active site, Na+ binding site, exosite-I and exosite-II (Figure 43a-b). Of these, exosite-I and
II are cationic domains located at approximately opposite ends of the thrombin molecule
and approximately 10–20 Å away from the active site.235

∗

In this paper, ‘specificity’ was defined as to the existence of a few, structurally unique HS sequences from a
combinatorial library of all possible sequences that can recognize the protein binding site in a single, welldefined binding mode. Therefore, specific HS sequences were determined by performing multiple molecular
docking experiments to assess the reproducibility of computed binding modes.
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Exosite-I, also called anion-binding site-I is located on the right of the active site
(‘east’ in standard view shown in Figure 43a) and is involved in binding fibrinogen. In
addition to fibrinogen, several other physiologic and non-physiologic anions bind in
exosite-I. For example, fibrin, coagulation factors V, VIII, and XIII, hirudin, bivalirudin,
dipetalogastin II, bothrojaracin, and many others interact with exosite-I.
Exosite-II, also called anion-binding exosite-II, is biophysically and spatially
discrete from exosite I and binds to highly-charged heparin. Thrombin exosite-II domain
include His91, Arg93, Arg101, Arg126, Arg165, His230, Arg233, Lys236, Trp237, and
Lys240 (Figure 43b). Thrombin exosite-II also interacts with heparan sulfate, chondroitin
sulfate and dermatan sulfate, and glycoprotein Ibα. Thrombomodulin interacts with both
exosites simultaneously by a hydrophobic domain in its EGF-like repeats to interact with
exosite-I and an anionic chondroitin sulfate sequence to interact with exosite-II.236
The binding of ligands in exosites I and II induces significant conformational
changes in the active site of thrombin. This allosteric effect has major influence on the
specificity and reactivity of thrombin towards its macromolecular substrates.236-239 For
example, the binding of thrombomodulin to exosite I alters the preference of thrombin
from fibrinogen to protein C. Similarly, the binding of heparin to exosite II induces a much
greater reactivity with antithrombin. Exosite II, being a more positively charged domain
than exosite-I, has a preference for sequences that contain a greater proportion of acidic
residues. This simple analysis is supported by binding energy contributions measured in
solution. Salt dependence studies of the dissociation constant of heparin–thrombin
interaction show ~80% contribution from ionic interactions.227
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Exosite II
60-loop

Exosite I
γ-loop
Na+ site

Figure 43a. Topology of thrombin. The thrombin surface is
shown in a space-filling representation in the standard
orientation using PDB entry 1PPB. Thrombin is bound to the
active site inhibitor D-Phe-Pro-Arg-chloromethylketone
(PPACK, shown in stick form). The surface shows the
orientations of exosites I and II (dark blue surface), the 60-loop
(orange surface) and the γ-loop (green surface), and the Na+
binding site (yellow surface). The active site is shown as a red
surface.
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Figure 43b. Thrombin exosite-II key amino acids interacting
with heparin octasaccharide. The crystal structure
representation is from Protein Data Bank entry 1XMN. Shown
is the important amino acids of exosite-II in different colors in
AB monomer of the crystal structure.

Exclusive exosite-II ligands GAGs do not alter the catalytic efficiency (kCAT/KM) of
thrombin and thus do not function as direct thrombin inhibitors (DTI).238,240,241 This
‘golden rule’ is likely to change with the discovery of some chemo-enzymatically prepared
lignin-based macromolecules, which have been found to reduce the kCAT of small peptide
hydrolysis by binding in or near exosite-II, the first in this class of DTIs.242,243
As discussed earlier heparin interaction at thrombin exosite-II is considered to be
non-specific interaction. In vitro, both high- and low-affinity heparins bind to thrombin
with an apparent KD of 0.7–2 µM, suggesting that the DEFGH structure is not critical for
thrombin binding.244 The µM affinity of heparin for thrombin arises from the presence of
an electropositive domain called exosite-II.
Equilibrium binding studies of heparin binding to thrombin by Olson et al. clearly
showed that heparin interaction is a non-specific electrostatic interaction.227 Their study
showed that the strong dependence of the thrombin-heparin binding interaction on NaCl
concentration, its minimal dependence on temperature, and the increase in apparent
binding affinity with increasing heparin oligosaccharide chain length were best accounted
for by a non-specific electrostatic association of thrombin with 5 to 6 anionic residues
contained in a 3-disaccharide binding site of heparin. This interaction was characterized by
an intrinsic dissociation constant (KD,obs) of 6-10 µM at physiological ionic strength (Table
7).227
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Table 7. Dissociation constants for thrombin-oligosaccharide interactions (Olson et al.).
Oligosaccharide

Non-specific binding model,

chain length

KD,obs µM

3-disaccharides (6-mer)

7.7±0.9

4-disaccharides (4-mer)

6.5±0.6

5-disaccharides (10-mer)

7.2±0.6

7-disaccharides (14-mer)

5.4±0.4

9-disaccharides (18-mer)

6.3±0.3

~13-disaccharides (26-mer)

10±1

The non-specific binding model of thrombin-heparin interaction is also supported
by the crystal structure study of thrombin bound to heparin octasaccharide.228 The crystal
structure of the α-thrombin and octasaccharide co-complex of 1.85 Å crystallographic
resolution (PDB entry 1XMN) is an asymmetric unit, consists of four thrombin monomers
denoted AB, CD, EF and GH, to reflect the two chains of the human α-thrombin monomer
(Figure 44). A heparin octasaccharide is sandwiched between two thrombin monomers, so
that the asymmetric unit comprises two nearly equivalent thrombin dimers AB-GH and
CD-EF. It should be noted that in the crystal structure 1XMN, only 6 residues of the
octasaccharide is resolved in the AB-GH dimer and 5 residues in the CD-EF dimer, and are
shown to bind in both directions; one running from the reducing end to the non-reducing
end (AB-GH) and the other running from the non-reducing end to the reducing end (CDEF) (Figure 44). Although the orientation of heparin is different in the two dimers, the
amino acids involved are from the same basic patch known as exosite-II.
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GH

EF

Reducing end
Non-reducing end

CD

AB

Figure 44. Ribbon representation of thrombin bound to heparin as observed in PDB structure 1XMN. The asymmetric unit
consists of four thrombin monomers crystallized into two nearly equivalent dimers AB-GH and CD-EF. The ribbon in gray
corresponds to monomer AB, green to CD, orange to EF and cyan to GH.

116

As discussed earlier, although electropositive residues line the HBS both in
antithrombin and thrombin, the antithrombin-heparin interaction is highly specific but the
thrombin-heparin interaction appears to be non-specific. We reasoned that although
arginine and lysine are the common residues in heparin binding site at thrombin and
antithrombin, there must be some critical differences in 3D geometry and topology,
flexibility of the side chains and their neighboring amino acids, and/or the
symmetry/asymmetry in the binding site. Those differences should determine the nature of
the heparin–protein interaction. We have used molecular modeling methodologies to
compare and contrast the nature of this unequivocally complex phenomenon of
specificity/non-specificity.
3.4.1. Questions Remaining Unanswered
The HBS of antithrombin and thrombin are lined with Arg and Lys residues.
Whereas the antithrombin-heparin interaction is specific, the thrombin-heparin interaction
is considered to be non-specific. Thus, the questions that arise include: What is the
structural and molecular basis for the specificity of the antithrombin-heparin interaction
and the non-specificity of the thrombin-heparin interaction? Is it possible to design ligands
that are specific for thrombin exosite-II?
3.4.2. Molecular Modeling: Specificity (Antithrombin) versus Non-specificity
(Thrombin)
A. Accessibility: Exposed Versus Buried Nature of the Flexible Side Chains
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The interaction of heparin with thrombin and antithrombin is primarily a chargebased interaction on the surface of the protein. The important amino acids involved in the
heparin binding site of antithrombin are Arg46, Arg47, Lys114, Lys125, Arg129 and
Arg132 (Figure 45a). Thrombin exosite-II consists of the basic amino acids Arg93,
Arg101, Arg126, Arg165, Arg233, Lys236 and Lys240 (Figure 46a).
As a first step toward identification of the differences in the residues responsible
for specific/non-specific interaction, the topology of the residues, in terms of the extent of
the surface exposure or the buried nature of the critical amino acids quantitatively, was
studied. The crystal structure of thrombin co-complexed with heparin used for this study
was the AB monomer of 1XMN, and for antithrombin, it was 1TB6, a ternary complex of
thrombin, antithrombin and heparin. Surface areas were calculated using the Fast Connolly
Surface in the MOLCAD module of SYBYL for each amino acid either within the context
of the protein crystal structure (exposed residue surface area in Table 8) or by itself (total
residue surface area in Table 8).
The surface area calculation indicates that in thrombin most of the basic amino
acids are more than ~60% surface exposed, except Arg101. In antithrombin, Lys114,
Lys125 and Arg129, the key residues considered to be more important in the recognition
phase of the antithrombin binding to pentasaccharide, are only 43-50% exposed (Figures
45b and 46b, Table 8). More surface exposure in thrombin allows flexible basic side chains
to adapt to structure of the ligand counterpart. However, less surface exposure in
antithrombin limits the access, requiring some kind of specific geometry in the ligand for
interaction.
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72
32

51

51

43
47
62

Figure 45a. Antithrombin: Key heparin binding site residues (PDB entry 1TB6); Figure 45b. Surface area exposure map
shown for critical amino acids in antithrombin, the heparin binding site (Red: Arg46, Orange: Arg47, Yellow: Lys114,
Green: Lys125, Cyan: Arg129 and Violet: Arg132). The number on the colored surface is the percent surface exposure of the
individual amino acids (Note: Arg132 is not a part of PBS, a subsite within the heparin binding site).
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61
25
52
79

59

60

69

Figure 46a. Thrombin exosite-II: Key heparin binding residues (PDB entry 1XMN); Figure 46b. Surface area exposure map
shown for critical amino acids in thrombin exosite-II (Red: Arg93, Orange: Arg101, Green: Arg165, Cyan: Arg233, Yellow:
Arg126, Blue: Lys 236 and Violet: Lys240). The number on the colored surface is the percent surface exposure of the
individual amino acids.
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Table 8. Surface area (SA) contribution and radius of gyration (Rg) analyses of the
important heparin-binding amino acids in antithrombin and thrombin.
ANTITHROMBIN
Amino

Exposed

Total

% Exposure

No. of

acid

Residue SA

Residue SA

R46

122.17

170.82

72

9

3.08

—

R47

54.51

169.37

32

13

0.32

S112, T115

W49

45.59

180.40

25

13

0.86

Aromatic*

K114

77.63

152.24

51

13

0.75

P12, F122#

K125

71.52

153.62

47

10

1.87

N45

R129

73.39

169.28

43

12

0.63

T44, E414

R132

101.84

163.08

62

8

3.46

—

Rg

H-Bond

Rg

observations

H-Bond
partner (s)

THROMBIN
Amino acid

Exposed

Total

% Exposure

No. of

Residue SA

Residue SA

H91

23.45

135.48

17

11

0.50

Aromatic*

R93

102.90

168.59

61

11

2.52

—

R101

42.70

169.43

25

11

0.77

D100

R126

114.37

164.69

69

10

3.10

E127†

R165

100.75

169.16

60

11

0.52

M180

H230

24.96

134.89

19

11

0.29

Aromatic*

R233

100.46

171.67

59

11

2.20

—

K236

122.33

154.62

79

7

3.29

—

W237

44.54

179.33

25

11

0.32

Aromatic*

K240

80.04

152.70

52

8

1.81

Q244

observations

partner (s)

*W49, H91, H230, and W237 are in fixed position due to the burial of hydrophobic aromatic ring.
#

Lys114 is held in place in antithrombin due to the hydrophobic influence of Phe122 and Pro12, which
thermodynamically favors Lys144 to stay close to the protein rather than being solvent-exposed.
†

E127 is adjacent to R126 in thrombin which could theoretically be an H-bonding partner but does not due to
the helical turn; they face away from each other.
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B. Flexibility: Calculation of Radius of Gyration (Rg)
The flexibility of the long basic amino acid side chains is expected to be another
contributing factor in determining specificity/non-specificity. The radius of gyration can be
used as a measure of the flexibility in basic amino acids in heparin binding sites. The
radius of gyration Rg is the root-mean-square distance (RMSD) of the points from their
center of mass (COM), and can be used as a measure of the variability in the position of
the basic side chain functionalities in the GAG binding sites (more details in experimental
section).
In order to calculate the radius of gyration, we collected from the Protein Data
Bank, thrombin and antithrombin crystal structures co-complexed with heparin or heparinbased ligands (Table 9). All antithrombins were aligned to the reference antithrombin
monomer from 1TB6 and thrombin monomers were aligned to the AB monomer of
1XMN. The alignments were performed using the Fit Monomers facility of SYBYL using
the residues depicted in figures 45a and 46a. When crystal structures were aligned, we
found that some amino acid residues are spatially conserved and some are spatially
divergent. Calculation of the radius of gyration identified the residues that are spatially
conserved in a quantitative manner.
In antithrombin, the pentasaccharide binding site amino acids Arg47 (Rg = 0.3 Å),
Lys114 (Rg = 0.8 Å), Arg129 (Rg = 0.6 Å) are highly spatially conserved in a series of
antithrombin crystal structures (Figure 47a). Lys125 exhibits modest spatial conservation
(Rg = 1.9 Å). Arg46 (Rg = 3.1 Å) and Arg132 (Rg = 3.5 Å, the EHBS amino acid) show a
very low degree of spatial conservation.
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In thrombin, the Arg93 (Rg = 2.5 Å), Arg126 (Rg = 3.1 Å), Lys233(Rg = 2.2 Å),
Lys236 (Rg = 3.3 Å) and Lys240 (Rg 1.8Å) positions are highly variable in a series of
thrombin structures indicating that they have high degree of flexibility in contrast to
antithrombin heparin binding site basic amino acids (Figure 48a). Interestingly, Arg101
(Rg = 0.8 Å) and Arg 165 (Rg = 0.5 Å) are highly spatially conserved. Although Arg233
has Rg = 2.2 Å, it can still be considered to be spatially conserved as (Figure 48a) it is
localized in only two groups indicating a bimodal distribution with a high degree of spatial
conservation within the two groups.
Although antithrombin and thrombin HBS are lined with Arg and Lys, based on
our study, their relative surface exposure and flexibility does not appear to be the same. So
we reasoned that there must be some differences in their surrounding amino acids. To find
out why some amino acids are spatially conserved and others are not, we closely examined
the environment or neighboring amino acids to see if there is anything structurally unique
that makes the long rotatable side chains of the key amino acids stay in a fixed
conformation. The ones that are spatially conserved had H-bonding partners within H-bond
distances (Figures 47b). This hydrogen bonding network anchors the side chain to a
particular orientation, which in turn makes some of the binding site basic residues uniquely
positioned to engage the ligands with certain structural features, but not others.
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Table 9. Crystal structures considered in the thrombin exosite-II and antithrombin PBS
basic residue analyses.
PDB ID

1JMO*

Chain
T
AT
AB
CD
EF
GH
LH
AD
BE
CF
LH

1TB6

LH

1XMN

3B9F
1E0F

Ra (Å)
1.85

Description
Thrombin-Heparin

Thrombin-Protein C Inhibitor-Heparin
Thrombin-Haemadin

1.60
3.10

Thrombin-Heparin Cofactor II

2.20

Antithrombin-Thrombin-Heparin

2.50

Antithrombin-Thrombin-Heparin
Mimetic (non-productive)

2.10

Missing residues
K236
K236, K240
R126
K236
K236, K240

Ref.
(228)

(245)
(246)

(247)
K240

(248)

I
2B5T

AB

(249)

CD
1SR5

I
A

2GD4

A
B
C
I
L
I
L
I
L
I

3EVJ

C
I

1T1F*

1AZX
1E03
1NQ9

R132
Antithrombin-AnhydrothrombinHeparin (mimetic)

3.27

Antithrombin (native)

2.75

Antithrombin (active)-Pentasaccharide
Antithrombin (latent)-Pentasaccharide
α-Antithrombin-Pentasaccharide

2.90
2.90

K125

(251)

Antithrombin-Heparin

2.60

R46, K125, R132
R46, R132

(250)

Antithrombin-S195A Factor XaHeparin

3.30

Antithrombin (Intermediate State)Natural Pentasaccharide

3.00

L

(250)

R47, K114, K125
R47, K114, K125
R47, K114, K125

(249)

(217)

(253)

R46, K125, R132

(254)

R46, R129, R132

a

Crystallographic resolution. *1T1F is not included in the calculation of radius of gyration (Rg), an outlier
that has incompletely built important amino acids including R47, K114 and K125 and is not an activated
form of antithrombin.
*
1JMO is not included in the calculation of radius of gyration, an outlier that is not bound to GAG.
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In the case of antithrombin, Arg47 (Hbond partners Ser112 and Thr115), Lys125
(Hbond partner Asn45) and Arg129 (Hbond partners T44 and Glu414) have H-bonding
partners within H-bond distances. Lys114 is held in place in antithrombin not because of
H-bond partners but due to the hydrophobic influence of Phe122 and Pro12, which
thermodynamically favors Lys144 to stay closer to the protein rather than solvent exposed
(Figure 47b). The same is true with thrombin, the residues that are in fixed orientation like
R101 (Hbond partner Asp100), R165 (Hbond partner Met180) and K240 (Hbond partner
Gln244) have H-bonding partners within H-bond distances (Figure 48b).
In summary, the heparin binding site amino acids in antithrombin are spatially
conserved and contribute to specificity, while in thrombin many of them are highly
flexible, which appears lead to considerable non-specificity.
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Figure 47a. The side chain conformation variation of the primary basic and other residues in antithrombin pentasaccharide
binding site (PBS) for a series of antithrombin crystal structures. The reference structure shown in this picture is from PDB
entry ‘1tb6’. The radius of gyration (ROG) is specified for each residue in angstroms and is shown as a dashed line. Sampled
points are shown as small spheres. Color code: blue = 1TB6, green = 1AZX, orange = 1E03, cyan = 1NQ9, red = 1SR5,
white = 2B5T, purple = 2GD4, tan = 3EVJ.
Figure 47b. H-bonding partners anchoring key side chains in antithrombin. The crystal structure The line in magenta shows
the distance between the hydrogen bonding atoms of the amino acids with distance in Å.*In Asn45, the position of Oxygen
and Nitrogen is interchanged from the crystal structure to show the possible H-bond between Asn45 and Lys125.
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Figure 48a. The side chain conformation variation of the primary basic and other residues in thrombin Exosite II for a series
of thrombin crystal structures. The reference structure shown in this picture is from PDB entry ‘1xmn’. The radius of
gyration (ROG) is specified for each residue in angstroms and is shown as a dashed line. Sampled points are shown as small
spheres. Color code: red = 1XMN, yellow = 1TB6, green = 3B9F, cyan = 1E0F, blue = 2B5T.
Figure 48b. H-bonding partners anchoring key side chains in thrombin (PDB entry ‘1xmn’). The line in magenta shows the
distance between the hydrogen bonding atoms of the amino acids with distance in Å.
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C. Symmetry/Asymmetry
Ionic sulfate-Lys and sulfate-Arg interactions may be approximately treated as
equivalent and non-directional. Thus, the spatial arrangement of the basic amino acid
residues in the heparin binding sites becomes more important in addition to surface
exposure and flexibility in determining specificity. Ligands that recognize a binding site
of high symmetry may exhibit more binding modes than those that recognize a lowersymmetry binding site.
In antithrombin, there are three important amino acids involved in heparin
pentasaccharide binding including Lys114, Lys125 and Arg129. In thrombin, there are at
least seven basic amino acids involved in heparin octasaccharide binding including Arg93,
Arg101, Arg126, Arg165, Arg233, Lys236 and Lys240. Figure 49a-b shows some
examples of how different geometry can impact the ways in which the ligand can interact
with the target protein.
Analysis of the relative geometrical position and shape of the antithrombin binding
site shows that it has an element of asymmetry in the binding site (Figure 50a). Lys114,
Arg125 and Arg129 forms a scalene triangle that restricts the number of ways in which
ligand can interact which favors the specific interaction with pentasaccharide (Note also
that Lys125 is somewhat flexible, allowing the three important residues of the PBS to
match the isosceles triangle).
In case of thrombin, we see an approximate element of symmetry that explains the
apparent contradiction that even with more interacting points instead of providing
specificity, thrombin exhibits non-specific interaction with heparin. When roughly divided
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by placing a line between R101 and R126, exosite-II shows 2 equivalent points of
interaction on either side in a linear fashion (Figure 50b). On the right side of the vertical
are R233 and R165 and on the left side are K236 and K240. On the top is R101 and on the
bottom is R126. This resembles the square/cross model symmetry with the distribution of
positively charged amino acids in a symmetric fashion (Figure 49a). This symmetrical
distribution of basic amino acids in exosite-II favors the non-specific interaction of heparin
oligomers.
Even though thrombin exosite-II appears to be a target for non-specific heparin
interaction, we have identified some spatially conserved amino acids in the upper-righthand corner of thrombin exosite-II including Arg101, Arg165 and Arg233 that may
represent a locally specific sub-pocket within exosite-II. This finding suggests that it may
be possible to design specific sequences that recognize the spatially conserved residues in
exosite-II. This would likely change the spectrum of future developments in thrombin
exosite-II- related research.
4 Degenerate

Square/Cross

Figure 49a. Symmetric four-point receptor geometry (square/cross) with multiple
degenerate binding modes for ligands.
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Receptor

Ligand
: 1 Pose

Equilateral Triangle

3 Degenerate

: 1 Pose

A

B

Isosceles Triangle

2 Degenerate

C
Scalene Triangle

1 Pose

D
Figure 49b. A. Equilateral triangle receptor (‘three-point pharmacophore’) showing limited binding mode for the typical Rand S- isomer of tetrahedral ligands. Three substituents (represented by different shapes) are non-equivalent. B. Lys-sulfate or
Arg-sulfate kind of non-directional interactions exhibit multiple binding modes in equilateral triangle receptor geometry. C.
Isosceles and D. Scalene triangles show single binding mode.
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Figure 50a. Asymmetry in antithrombin pentasaccharide binding site (PBS). Scalene triangle geometry is present between
three important pentasaccharide binding amino acids Lys114, Lys125 and Arg129 responsible for specificity.
Figure 50b. Element of symmetry in thrombin exosite-II. A vertical line between Arg101 and Arg126 divides exosite-II
approximately into two equal parts. Lys236 and Lys240 are on the left side of the horizontal axis. Arg233 and Arg165 are on
the right side of the horizontal axis. This element of symmetry favors non-specific interaction. The isosceles triangle (Green
lines) between the spatially conserved Arg101, Arg165 and Arg233 on the right side of the symmetry represents a local
spatially conserved asymmetry.
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3.4.3. Molecular Docking of Library of Heparin Octasaccharide Sequences
A. GOLD Predicts the Binding Geometry of Natural Octasaccharide to
Within 3 Å
The crystal structure of α-thrombin and octasaccharide co-complex of 1.85 Å
crystallographic resolution from PDB entry 1XMN was used for molecular docking. The
crystal structure asymmetric unit consists of four thrombin monomers denoted AB, CD, EF
and GH, to reflect the two chains (heavy and light) of the human α-thrombin monomer. A
heparin octasaccharide is sandwiched between two thrombin monomers, so that the
asymmetric unit comprises two nearly equivalent thrombin dimers AB-GH and CD-EF. It
should be noted that in the crystal structure 1XMN, only 6 residues of the octasaccharide
are resolved on the AB-GH dimer and 5 residues on the CD-EF dimer. These are shown to
bind in both directions: one running from the reducing end to the non-reducing end (ABGH) and the other running from the non-reducing end to the reducing end (CD-EF) (Figure
44). Since the AB-GH dimer in the crystal structure represents the maximal primary
interactions between thrombin and heparin this dimer was considered for docking
experiments.228
In order to test whether the GOLD docking program is able to dock the crystal
structure octasaccharide sequence reasonably within the predefined binding site as in the
crystal structure, the natural octasaccharide was docked onto the thrombin dimer in
exosite-II. On comparison of docked solution to the backbone of hexasaccharide in crystal
structure, the docked solutions were found to be within 3 Å of the crystal structure. Among
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the docked poses, the top 6 solutions (2 solutions × 3 docking experiments) were well
within 2.5 Å in repeated experiments. Although the docked solution of octasaccharide
backbone approximately matches the crystal structure, the directionality is opposite (Figure
51). This preliminary experiment shows that our protocol for docking of GAGs to the
thrombin exosite-II reliably reproduces one of the two binding orientations and supports
the non-specific nature of the thrombin-heparin interaction.

Non-Reducing End
Reducing End

Reducing End

Non-Reducing End

Figure 51. Comparison of the binding orientations of the docked solution of
octasaccharide to the observed octasaccharide fragment in the crystal 1XMN. The
octasaccharide backbone of the docked solution approximately matches the crystal
structure but the directionality is opposite. In the crystal structure, only 6 residues of the
octasaccharide are resolved on the AB-GH dimer and 5 residues on the CD-EF dimer, and
are shown to bind in both directions: one running from non-reducing end to reducing end
and the other running from reducing end to non-reducing end. (See details in experimental
section). Docking predicts one of the two binding modes for the octasaccharide. Docked
solution of the octasaccharide (green) and the binding mode of the 6 residues of the
resolved crystal structure octasaccharide (cyan) are shown as ball-and-stick models.
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B. Docking of a Library of Octasaccharide Sequences: Selected Sequences
Preferentially Bind to Thrombin.
The crystal structure thrombin co-complex with octasaccharide is considered to be
a reference in deciding the length of the heparin oligomers (1XMN) to be tested for
specificity. As discussed earlier, 48 different disaccharide building blocks of GAGs are
possible, of which only 23 are known to exist. If we use all 23 building blocks and include
both 1C4 and 2SO conformations for iduronic acid-containing disaccharides (23+13) to
build the octasaccharide, the virtual library would result in (36×36×36×36) 1,679,616
sequences (Figure 38b). This is computationally a very challenging task. To limit our
preliminary experiment, we have narrowed the number of disaccharide building blocks to
8, based on the common disaccharides present in heparin octasaccharide structure with
varying sulfation pattern (Figure 52).

HS14a and HS14a_1C4 (Charges: 2)

HS20a and HS20a_1C4 (Charges: 3)

HS15a and HS15a_1C4 (Charges: 3)

HS21a and HS21a_1C4 (Charges: 4)

Figure 52. Building blocks for heparin oligomers used to build the octasaccharide library
of 4096 sequences. Disaccharide units are named as HS+number+a where ‘a’ denotes an
additional sulfate group at 2nd position of the iduronic acid. Since iduronic acid can exist in
1
C4 or 2SO forms, a suffix 1C4 is added. No suffix indicates 2SO conformation.
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The octasaccharide library of 4096 sequences was built in SYBYL in an automated
manner using an in-house SPL (SYBYL Programming Language) and was docked to the
AB-GH thrombin dimer using GOLD v3.0 (See experimental section for details). In the
first phase of the docking program, GOLD filtered high-affinity sequences from the 4096
sequences, whose modified GOLDScore followed a Gaussian distribution. These
sequences were then subjected to the specificity filter (Figure 53).
1200
1006
1000

881

821

FREQUENCY

800
600

513
431

400
238
200
41

x ≤ 40

40 < x ≤ 50

118
17

30
120 < x

110 < x ≤ 120

100 < x ≤ 110

90 < x ≤ 100

80 < x ≤ 90

70 < x ≤ 80

60 < x ≤ 70

50 < x ≤ 60

0

X= GOLD SCORE DISTRIBUTION

Figure 53. Histogram showing the distribution of 4096 octasaccharide sequence modified
GOLDScore following the first phase of combinatorial library screening with thrombin.
The top-scoring sequences (~1%) from the first phase are then docked in triplicate
under more rigorous docking conditions. Application of the specificity filter (top 2
solutions from each experiment must be within 2.5 Å) resulted in 14 hit sequences for
thrombin dimer (Table 10).
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Table 10. Modified GOLDScore for hit octasaccharide sequences of a library of 4096
heparin oligomers. The score in the table represents the maximum score for 3 independent
docking runs.
HIT SEQUENCES

Run 1

Run 2

Run 3

Max. score

HS20a_1C4__HS14a__HS15a__HS20a_1C4

112

129

138

138

HS20a_1C4__HS20a__HS15a__HS20a_1C4

134

110

137

137

HS21a_1C4__HS20a__HS21a__HS20a_1C4

134

114

119

134

HS21a_1C4__HS21a__HS21a__HS20a_1C4

131

118

121

131

HS21a__HS21a_1C4__HS21a_1C4__HS15a_1C4

108

128

108

128

HS20a_1C4__HS21a__HS21a__HS20a_1C4

120

126

112

126

HS21a_1C4__HS21a_1C4__HS21a_1C4__HS21a_1C4

116

101

126

126

HS21a_1C4__HS21a__HS15a__HS14a_1C4

121

124

112

124

HS21a_1C4__HS21a__HS20a__HS20a_1C4

107

122

112

122

HS15a__HS21a_1C4__HS14a_1C4__HS15a_1C4

121

93

94

121

HS21a__HS21a__HS15a__HS20a_1C4

120

121

106

121

HS14a_1C4__HS21a__HS15a__HS20a_1C4

110

117

106

117

HS20a__HS20a__HS15a__HS21a

109

103

110

110

HS20a__HS21a__HS15a__HS20a

108

107

110

110

These sequences fall into two general pattern of binding orientation, one with nonreducing end to reducing end (Binding mode A) and another with reducing end to nonreducing end (Binding mode B) (Figure 54). This is fully in consistent with what is
observed in the crystal structure 1XMN wherein the AB-GH and CD-EF dimers of
thrombin show opposite orientations for the octasaccharide in exosite-II.
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Sequences with binding mode B

Red-filled hexagon: Iduronic acid
with 2So conformation; Blue-filled
hexagon: Iduronic acid with 1C4
conformation; Unfilled hexagon:
Glucosamine; Solid green line:
Presence of N-sulfate or O-sulfate;
Solid red line: Absence of Nsulfate or O-sulfate.

Sequences with binding mode A

Figure 54. Cartoon representing
the hit sequences identified by
docking of the octasaccharide
library shows 2 binding modes in
thrombin exosite-II

Out of the final 14 sequences, 11 of them follow binding mode A. Although it
seems that both binding geometries are possible, one binding mode is preferentially
selected over the other. A comparison of the binding modes and structural features of the
sequences show that sequences having the 1C4 conformation for units 3 and 5 adopt
binding mode B. On the other hand, 11 sequences adopt binding mode A and are uniquely
different by having the 2SO conformation at units 3 and 5. This subtle difference in the
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conformation reverses the direction in which octasaccharide binds to thrombin at exositeII. Just as observed in the crystal structure, most of the octasaccharide interactions are
observed with the AB monomer of thrombin and few interactions with the GH monomer
(R93 and K240 only).
C. Design of Smaller Sequences for Thrombin Exosite-II
Molecular docking of the library of octasaccharides showed that the important
critical interactions are from the central part of the octasaccharide while the end residues
flank the thrombin exosite-II. Based on this observation, we decided to build a small
library of tetra-, hexa-, and octasaccharides based on the highly-sulfated disaccharide
shown in Figure 55 to test if the shorter sequences will be able recognize the same binding
mode. If so, it may serve as a framework to design ‘specific’ sequences that recognize the
spatially conserved residues in exosite-II (see Section 3.4.1).

HS21a and HS21a_1C4
Figure 55. Structure of a highly-sulfated iduronic acid containing disaccharide. Both 1C4
and 2SO forms are considered. Negatively charged groups are indicated with ovals.
The small library consisting of 4 tetrasaccharide, 8 hexasaccharide and 16
octasaccharide sequences was docked in triplicate to exosite-II of the AB-GH dimer of
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thrombin crystal structure 1XMN. The 2 top-scoring solutions of each hit tetra-, hexa-,
and octasaccharides were within 2.5 Å in triplicate experiments. The analysis of binding
modes shows that, regardless of the size of the sequences, there exists a common binding
motif for these sequences where certain interactions are always consistent in each case
(Figures 56 and 57).

SEQUENCE

NO. OF CHARGES

GOLD SCORE

TETRA_PER_SO3

8

118

HEXA_PER_SO3

12

155

OCTA_PER_SO3

16

145

Figure 56. Cartoon showing the hit tetra-, hexa-, and octasaccharides and their interaction
with thrombin exosite-II amino acids. The tetrasaccharide sequence is a substructure
contained within the octasaccharides and maintains the same interaction profile at
thrombin exosite-II regardless of the size of the sequence. From this, a core tetrasaccharide
pharmacophore is elucidated. The table lists the hit sequences, the number of charges and
their corresponding modified GOLDScores. A green star represents O-sulfate or N-sulfate,
and a red cup represents carboxylate.
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Figure 57. Docking poses of tetra- (green), hexa- (cyan) and octasaccharide (magenta)
sequences in thrombin exosite-II. All of them have similar binding mode running from
non-reducing end to reducing end. The ribbon representation of the AB monomer of the
crystal structure 1XMN is displayed (monomer GH not displayed for clarity). Thrombin
exosite-II amino acids are shown in capped stick representation.
A closer look at these sequences and their interaction with thrombin exosite-II
amino acids revealed that it may be possible to remove certain non-interacting redundant
sulfate groups in the central core tetrasaccharide pharmacophore. But is it possible to
remove these functionalities and still retain the same binding mode? To study the impact of
the absence of these non-interacting groups in determining the binding mode, we have
removed certain non-interacting sulfate groups in these hit sequences in the tetrasaccharide
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region and docked them in triplicate to thrombin exosite-II (Figure 58). The result showed
that, these sequences recognize the same amino acids and were docked consistently in the
same binding mode even after removing some charges, which confirmed our optimism that
designed sequences would specifically recognize spatially conserved amino acids in
thrombin exosite-II (Figures 58 and 59). It is important to recall that this interaction has
been considered to be a non-specific interaction.
Table 11. Modified GOLDScore for the sequences docked consistently in thrombin
exosite-II.
HIT SEQUENCES

MODIFIED
GOLDScore

AVERAGE*

HS21a__HS21a_1C4

108

113.0

HS21a_1C4__HS21a

118

TETRASACCHARIDE

HEXASACCHARIDE
HS21a__HS21a__HS21a

142

HS21a__HS21a__HS21a_1C4
1

135
1

HS21a__HS21a_ C4__HS21a_ C4

134

HS21a_1C4__HS21a_HS21a

155

141.5

OCTASACCHARIDE
HS21a__HS21a__HS21a__HS21a

123

HS21a__HS21a__HS21a__HS21a_1C4
1

132

1

1

HS21a__HS21a_ C4__HS21a_ C4__HS21a_ C4

125

HS21a_1C4__HS21a__HS21a__HS21a

132

HS21a_1C4__HS21a__HS21a__HS21a_1C4

145

HS21a_1C4__HS21a_1C4__HS21a__HS21a

111

*The GOLD score average for the subset of sequences of a given length.
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126.0

HIT SEQUENCES

MODIFIED
GOLDScore

TETRASACCHARIDE
HS14a__HS15
HS15a__HS15
HEXASACCHARIDE
HS21a_1C4__HS14a__HS15
HS21a_1C4__HS15a__HS15
OCTASACCHARIDE
HS21a_1C4__HS14a__HS15__HS21a_1C4
HS21a_1C4__HS15a__HS15__HS21a_1C4

100
106
111
127
112
126

Figure 58. Cartoon showing the hit tetra-, hexa-, and octasaccharides with fewer charges
and their interaction with thrombin exosite-II amino acids. The tetrasaccharide sequence is
also a part of hexa-, and octasaccharide which is maintaining the same interaction profile at
thrombin exosite-II even after removing some of the redundant charges from the
sequences. The accompanying table lists the sequences and their modified GOLDScores.
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Figure 59. Docking poses of tetra- (green), hexa- (cyan) and octasaccharide (not shown for
clarity) sequences in thrombin exosite-II. These sequences are stripped of some redundant
charges and still maintain the same binding mode just like their highly-sulfated
counterparts. All of them have a similar binding mode running from non-reducing end to
reducing end. Important thrombin exosite-II amino acids in the AB monomer of the crystal
structure 1XMN are displayed in capped stick representation. These are the sequences with
only the “minimally required” sulfate groups (in the conserved tetrasaccharide region),
displayed without the ribbon.
These sequences with only the “minimally required” sulfate groups not only
docked consistently in repeated experiments but also recognized the spatially conserved
Arg101, Arg165, and Arg233, which approximate isosceles triangle geometry in thrombin
exosite-II. This indicates that an optimally designed heparin sequences may bind to
thrombin exosite-II in a specific manner (Figure 59).
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D. Designing ‘High Affinity’ and ‘High Specificity’ Tetrasaccharide Sequences as
Thrombin Exosite-II Modulators
Although it is presumed that the heparin-thrombin interaction is non-specific, our
molecular modeling study showed that there is a region within exosite-II with significant
spatial conservation including amino acids Arg101, Arg165 and Arg233. These amino
acids assume isosceles triangle geometry with a local asymmetry in a symmetrical
thrombin exosite-II. Docking experiments showed that a unique tetrasaccharide sequence
was docked consistently in the same binding mode in exosite-II recognizing the above
mentioned amino acids. The binding mode for this unique tetrasaccharide is consistent in
multiple docking experiments.
This observation of specific binding mode of tetrasaccharide sequence is not
changed even after removing the non-interacting groups (redundant charges) on the
tetrasaccharide. When the binding modes of tetrasaccharide sequences were analyzed, we
found that the 2-O-sulfate in the non-reducing end iduronic acid was not close enough to
effectively H-bond with Arg101, but instead faced Arg233. Based on distance and
geometry calculations, we hypothesized that a 3-O-sulfate in the same ring would be
optimal to gain interaction with Arg101 and additionally to Arg93. To test this hypothesis
we designed the following tetrasaccharide sequences where in one case we simply
substituted 2-O-sulfate by 3-O-sulfate and in another case added 3-O-sulfate in addition to
the existing 2-O-sulfate in the non-reducing end (Figure 60).
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HS15a_3-O-SO3 (No_2-O-SO3) __HS15: GOLD Score 118

HS21a_1C4__HS21a: GOLD Score 118

HS15a_3-O-SO3__HS15: GOLD Score 127
Figure 60. ‘High affinity’ and ‘high specificity’ tetrasaccharide sequences. The sequence
in the middle is the highly-sulfated sequence with 8 charges that served as a
pharmacophore in designing sequences with fewer charges. Appropriately placing the
charges in the tetrasaccharide framework yields sequences of equal or higher GOLD score.
The circled positions were modified in generating new sequences.
Docking of these designed sequences with fewer charges resulted in equal or higher
GOLD scores in repeated experiments and each time when they were docked they docked
in the same binding mode with less than 1 Å RMSD (Figure 61). As shown in Figures 60
and 62 the initial hit tetrasaccharide has 8 charges and has a GOLD score of 118. The
sequences we have designed are the same size but with 5 or 6 charges; these have equal or
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higher GOLD score (127) and predicted to recognize the same binding mode including the
spatially-conserved R101, R165, and R233 and also make accessory interactions with
R126 and R93, making a strong case for ‘specific’ exosite-II modulators.

Figure 61. Docking poses of ‘high affinity’ and ‘high specificity’ tetrasaccharide
sequences shown in green (ball-and-stick) is the highly-sulfated reference structure. Blue
and magenta (capped stick) are the sequences with fewer charges. Sequences are docked to
within 1 Å RMSD. Important thrombin exosite-II amino acids in the AB monomer of the
crystal structure 1XMN are displayed in capped stick without the backbone ribbon.
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Figure 62. Cartoon structures representing the ‘high affinity’ and ‘high specificity’
sequences and their binding amino acids in thrombin exosite-II
The newly-designed ‘best hit’ HS15a_3-O-SO3__HS15 sequence is 50% smaller in
size and has 62.5% fewer charged functionalities but has a nearly equal GOLD score in
comparison to the hit octasaccharide sequences that have 13-16 charges (Figure 63). Not
only is this tetrasaccharide smaller in size with fewer charges, but has a better probability
of making ‘specific’ interactions at thrombin exosite-II.
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HS21a_1C4__HS15a__HS15__HS21a_1C4: GOLD Score 126

HS15a_3-O-SO3__HS15: GOLD Score 127
Figure 63. Structure of hit octasaccharide and tetrasaccharide sequences.
The average GOLD score for the fully-sulfated hit octasaccharide sequences is 126.
The GOLD score for the designed tetrasaccharide with only 6 charges is 127. This shows
that we have designed tetrasaccharide sequences with the essential pharmacophore to
recognize the important amino acids in thrombin exosite-II in a ‘specific’ manner. Our
optimism is partly based on the reproducibility of the docking results predicting the same
binding mode in repeated experiments. This design challenges the much-believed concept
of non-specific interaction of heparin to thrombin exosite-II. Since heparin is larger and
has many more charges, it can interact many different ways at thrombin exosite-II. This
presumably would not be true for the small designed tetrasaccharides.
3.5. Summary and Conclusions
Heparin, a clinically used anticoagulant exhibits its effect by interacting with
antithrombin and thrombin. Heparin also interacts with many other proteins besides
antithrombin and thrombin, a property which is responsible for its side effects. However, a
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heparin pentasaccharide sequence specifically recognizes antithrombin and this interaction
has been studied extensively. Although the antithrombin–heparin interaction is considered
a specific interaction, the architecture responsible for specificity in antithrombin remains
unclear.
Our molecular modeling studies of antithrombin crystal structures explain some of
the factors that are responsible for specificity. Even though, one would expect long side
chain amino acids, such as Lys and Arg, that form the heparin binding site (HBS) in the
surface of the antithrombin to be highly surface exposed, it was found that most of the
critical amino acids in HBS are instead ~60% buried. In addition to the buried nature, they
are also held in place by neighboring H-bonding partners such Asp and Glu, which restricts
the flexibility of the long side chains. In some cases, like Lys114, the hydrophobic
environment keeps the long side chains close to the protein rather than solvent exposed.
Calculation of radii of gyration indicated that most of the critical amino acids in HBS are
spatially conserved. Analysis of the relative geometry revealed an important feature where
Lys114, Lys125 and Arg129 form a non-equilateral scalene triangle, which in principle
would favor specific interaction and require a complementary match from the ligand to be
recognized. Since pentasaccharide is a molecule with appropriately distributed charge
functionalities that meet the 3D geometrical requirements of antithrombin HBS, the
antithrombin-pentasaccharide interaction becomes specific rather than just ionic driven
interactions between negatively charged ligand and positively charged protein.
At the same time the heparin-thrombin interaction is presumed to be non-specific
even though the type of interaction is same as antithrombin. In contrast to antithrombin,
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we found that most of the basic long side chain amino acids in thrombin exosite-II are
more than ~60% surface exposed and are highly flexible. Also the important amino acids
in thrombin exosite-II form an approximate symmetric model which favors non-specific
interaction.
Calculation of radii of gyration showed that within this non-specific favored
thrombin exosite-II, some amino acids are spatially conserved including Arg101, Arg165
and Arg233, forming a local asymmetric center. Using molecular docking experiments, we
have designed novel tetrasaccharide sequences to specifically recognize these amino acids.
The newly designed ‘best hit’ HS15a_3-O-SO3__HS15 sequence is 50% smaller in size
and contains 62.5% fewer charged functionalities but has a nearly equal GOLD score in
comparison to the hit octasaccharide sequences that have 13 to 16 charges. This
tetrasaccharide is not only smaller in size with fewer charges but has better probability of
making ‘specific’ interactions at thrombin exosite-II based on our repeated docking
experiments.
The design of novel ‘specific’ tetrasaccharide sequences challenges the existing
idea that the thrombin–heparin interaction is non-specific and leads to the possibility of
designing and synthesizing of heparin-based specific thrombin exosite-II modulators.
Since we have already shown in our lab that it is possible to replace the saccharide
backbone by a non-saccharide skeleton in designing non-saccharide antithrombin
activators, in principle it is also possible to design non-saccharide mimics based on this
novel sequence for thrombin exosite-II.
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3.6. Computational Methods
Software/Hardware: SYBYL 7.1 (Tripos Associates, St. Louis, MO) was used for
molecular visualization, for minimization, and for adding hydrogens to protein structures
from the Protein Data Bank. All modeling was performed on an IRIX 6.5-based SGI Tezro
graphical workstation. GOLD, version 3.0, was used for docking experiments. Heparin
oligomeric sequences were built combinatorially in an automated manner using in-house
SPL (SYBYL Programming Language) scripts.
Energy Minimizations: Heparin oligomers and thrombin structures were energyminimized to get optimal geometric conformation. Except where stated, energy
minimization was performed using the Tripos Force Field with Gasteiger-Hückel charges,
a fixed dielectric constant of 80, and a non-bonded cutoff radius of 8 Å. Minimization was
carried out for a maximum of 5000 iterations subject to a termination gradient of 0.05
kcal/(mol-Å).
Protein Coordinates: The coordinates for the thrombin dimer ABGH were extracted from
the crystal structure of the thrombin-heparin complex (PDB entry 1XMN). Hydrogen
atoms were added in SYBYL 7.1, and the structure was minimized with fixed heavy-atom
coordinates using the Tripos force field for 1000 iterations subject to a termination gradient
of 0.05 kcal/(mol-Å).
Coordinates for Natural Heparin Octasaccharide: In the 1XMN thrombin-heparin
crystal structure, thrombin was crystallized as a tetramer with 1 heparin sequence for each
dimeric partner. In total, for 4 thrombin units there are 2 heparin sequences. Though they
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have used octasaccharide for crystallization, in one dimer the heparin sequence was
resolved only up to 6 saccharide units (AB-GH) and 5 units in the other dimer (CD-EF). In
order to build the natural octasaccharide, the crystal structure-resolved hexasaccharide was
extracted from the crystal structure and 1 saccharide unit has been added to both ends of
the hexasaccharide. In SYBYL, the atom type of sulfur and oxygen atoms in SO3 groups
were modified to S.o2 and O.co2, respectively, and the bond type between these atoms
were modified to aromatic bond. Hydrogen atoms, absent in the PDB structure, were added
in SYBYL, and the resultant structure was minimized to optimize the geometry of
hydrogen atoms only (no change in non-H atoms) at an average ФHΨH values for interglycosidic torsion angles using the same protocol for building glycosaminoglycan (GAG)
sequences as reported previously.109
Coordinates for Heparin Oligomers: The coordinates for the heparin oligomeric
sequences were generated using a series of SPL scripts and a set of 8 disaccharide building
blocks. Although the number of possible Heparin-Like GAG [UAp (1→4) GlcNp]
disaccharides is 48, only 23 have been experimentally observed. On the basis of natural
octasaccharide sequence, we restricted our library to include only IdoAp sequences that
contain IdoAp2S and do not contain GlcNp3S. Because IdoAp residues in heparin can
exist either in the 2SO or 1C4 conformations, each IdoAp residue was modeled explicitly in
these two different states. Thus, our virtual library of octasaccharide consists of 8 IdoApcontaining disaccharide building blocks (Figure 52). 2SO-IdoAp-containing disaccharides
were generated using the GH residues from the 1TB6 co-crystal structure as template,220,248
while the template for the 1C4-IdoAp disaccharides was obtained from the 1BFC
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structure.255 Appropriate side-chain modifications were made to generate the 8 building
blocks. Each disaccharide was minimized at the average ФHΨH value subject to a
restraining force constant of 0.01 kcal-mol-1-deg-2. The 8 disaccharides were then used to
build a combinatorial HS octasaccharide library using an SPL script, following which each
sequence was minimized with 10000 iterations as described above in an automated
manner. Thus, the HS combinatorial library contained 8×8×8×8 = 4096 octasaccharide
sequences.
Crystal Structures for Specific and Non-specific Interaction:
To explore the specific/nonspecific interaction of heparin to antithrombin and
thrombin, we have used the reported crystal structures of antithrombin and thrombin cocrystallized with heparin fragments. The list of antithrombin and thrombin crystal
structures used for this study with their PDB entry and reference is reported in Table 9.
Theoretical Background for Calculation of Radius of Gyration:
The radius of gyration is often used as a measure of the compactness of a group or
cluster of points. To measure the radius of gyration, first the center of mass (COM,
Equation 1) of the set of n points with masses mi is calculated:
∑
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∑
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The COM is the point in 3D space where all of the masses are perfectly balanced.
If all of the masses are equal, which is true in our case (we are using either the Cζ carbon
atom [for the Arg residues] or the Nζ nitrogen atom [for the Lys residues]), the COM is just
the average position of the n individual point masses (Equation 2):
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The distance r between two points (x1, y1, z1) and (x2, y2, z2) is given by Equation 3:
(3)
The moment of inertia I of the set of masses rotating about the COM is the product
of the mass and the square of the distance from the COM for each point (Equation 4):
(4)

I is dependent on the number of points, their individual masses, and their distances
from the COM. If the masses are all equal to m, then Equation 4 may be simplified to
Equation 5:
(5)
Multiplying the right-hand side of Equation 5 by unity (n/n) gives Equation 6:
∑

(6)

The total mass of the points is nm. Now, imagine that all of this mass is distributed
evenly in a thin layer on the surface of a sphere, such that the moment of inertia I is the
same as that for the individual points. The radius of gyration Rg is the radius of this
sphere, where M is the total mass of the system:
(7)
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Rearranging Equation 7 and solving for Rg:
(8)
Substitution of Equation 6 for I, nm for M and simplification yields:
∑

(9)

Thus, when all of the masses are equal, Rg is the root-mean-square distance
(RMSD) of the points from their COM (Equation 9), since in general
∑

(10)

Where d is a general distance measurement between two arbitrary points. The two
points could represent (for example) a lysine side chain nitrogen atom and the COM as in
Equation 9. Alternatively, the two points could represent the position of a particular atom
in two different docked poses of the same ligand, as we do when we analyze the similarity
of docked GAG backbone positions.
Docking of Heparin Oligomers:
Docking of saccharide ligands onto the AB-GH dimer of thrombin (PDB ID =
1XMN) was performed with GOLD v.3.0. The binding site in thrombin was defined based
on the crystal structure ligand resolved 6 unit ‘hexasaccharide’ of the octasaccharide as a
reference with any amino acid residues within and around the ligand for 18 to 20 Å in the
protein. This definition of the binding site covers all important known exosite II residues
including H91, R93, R101, R126, R165, R233, K236, K240, and W237.
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GOLD is a “soft docking” method that implicitly handles local protein flexibility
by allowing a small degree of interpenetration, or van der Waals overlap, of ligand and
protein atoms. GOLD also optimizes the positions of hydrogen-bond donating atoms on
Ser, Thr, Tyr, and, most importantly, Lys residues as part of the docking process. Whereas
all saccharide bonds were constrained for the rigid body docking experiment, only the
inter-glycosidic bonds were constrained when docking structures with the average torsion
angles. Unless specified otherwise, default parameters were employed during the GOLD
docking runs.
For the smaller set of tetra-, hexa-, and octasaccharide sequences, docking was
performed using no speed-up and a genetic algorithmic search with a default automatic
setting to determine the appropriate iterations by GOLD based on the number of rotatable
bonds in the sequence. In this search, GOLD starts with a population of 100 arbitrarily
docked ligand orientations, evaluates them using a scoring function (the GA fitness
function) and improves their average “fitness” by an iterative optimization procedure that
is biased toward high scores. As the initial population is selected at random, several such
GA runs are required to more reliably predict correct bound conformations. In this study
10 GA runs were performed with the GOLD score as the fitness function. Collectively,
these 10 GA runs are referred to as one docking experiment. In addition, to enhance speed,
the GA was set to pre-terminate if the top two ranked solutions were within 2.5 Å RMSD.
Docking experiments were performed in triplicate to ensure reproducibility and to reduce
false positives. The top two solutions of each docking experiment were considered for
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further analysis. Thus, a typical triplicate docking experiment would yield a minimum of
six solutions.
When docking the octasaccharide combinatorial library made from 8 disaccharide
building blocks, a two-step docking protocol was utilized. The first step consists of
screening all possible sequences using 30000 GA iterations (7 to 8× speed up) and GOLD
score evaluation of only the top-ranked solution. This step identified the most promising
sequences (top 1%) that have a relatively high GOLD score. The second step consisted of
docking these most interesting sequences in triplicate for 300,000 iterations. Docking was
driven by the GOLD scoring function. Although this scoring function correlates with the
observed free energy of binding, a modified form of the scoring function has been found to
be more reliable.256 This modified GOLDScore, which utilizes hydrogen-bonding and van
der Waals interactions (eq. 1), was used to rank the final docked solutions.
1.375

(11)

Where, HBext and VDWext are the “external” (non-bonded interactions taking place between
the ligand and receptor) hydrogen bonding and van der Waals terms, respectively. Unless
otherwise noted, the terms ‘GOLD Score’ and ‘modified GOLDScore’ in this work both
refer to Equation 11.
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CHAPTER 4
CONCLUSIONS

Numerous attempts have been made to design or discover new molecules that
activate antithrombin.158,160,207 However, each of these searches has relied on utilizing a
saccharide scaffold as a mimic of heparin. Implicit in these designs was the expectation
that a saccharide scaffold was necessary to induce antithrombin activation. Our research
group has challenged the assumption that the saccharide-based skeleton is essential for the
activity of specific glycosaminoglycan (GAG) sequences. We hypothesized that specific
GAG sequences can be replaced by non-saccharide skeletons which may provide several
advantages over the GAG skeleton. These include 1) ease of chemical synthesis; 2)
likelihood of oral delivery due to enhanced hydrophobic character; 3) opportunity to gain
additional non-ionic binding energy; 4) enhanced specificity for the target protein; and 5)
the ability to modulate responses in either an agonist or an antagonist manner.
Desai and co-workers have designed small, non-saccharide sulfated flavans based
on the trisaccharide DEF as a template using hydropathic interaction (HINT)210 analysis.
The reported sulfated flavans were found to be weak actvators of antithrombin. To improve
on

the

antithrombin

activation

potential

of

these

organic

activators,

a

tetrahydroisoquinoline-based bicyclic-unicyclic sulfated activator IAS5 was designed using
a pharmacophore-based approach by Raghuraman et al.209 These studies showed that IAS5
activates antithrombin nearly 30-fold, an increase of nearly 2- to 3-fold higher than the
first-generation rationally designed agents.134,135 However, the designed molecules were
158

found to be weak activators of antithrombin due to their binding to the extended heparin
binding site (EHBS) instead of the pentasaccharide binding site (PBS) of antithrombin.
To design better non-saccharide antithrombin activators, a virtual screening-based
approach, which categorizes the ligands as either PBS- or EHBS-binding molecules in
native and activated antithrombin, was employed. Combinatorial virtual screening of
24576 molecules based on a tetrahydroisoquinoline (ISOQ) core scaffold resulted in 92
hits that were predicted to bind preferentially in the PBS of activated antithrombin with
good affinity. The molecular modeling results lead to several hypotheses. Of special
importance are three hypotheses. The modeling results suggest 1) an optimal linker length
of the 4 to 5 atoms; 2) a 2′,5′-disulfated unicyclic ring; and 3) a 3,5,6-trisubstituted bicyclic
ring are predicted to be important. The hypotheses formed the basis for the synthetic work
currently in progress in the Desai laboratory.
As mentioned earlier, the synthesis of highly sulfated molecules is challenging.209
To date, no molecule with all three features has been synthesized. Yet, the laboratory has
just synthesized and tested one molecule that may serve as initial test of molecular
modeling experiments.

Activator 67A2L25
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The potential activator 67A2L25 was synthesized (by Mr. Al-Horani) and
evaluated (by Dr. Liang) using the standard antithrombin activation protocol developed by
the laboratory. Activator 67A2L25 has a 6,7-disulfated bicyclic ring (instead of 5,6disubstitution), a two carbon linker (instead of 4 or 5 carbon linker); and a 2,5disubstituted unicyclic ring (as desired).
Biochemical analysis of 67A2L25 shows an antithrombin activation potential in the
region of 50- to 100-fold (the high variance is because of the very high salt content as
impurity in the sample). The activation potential of 67A2L25 is much less than full
antithrombin activation (300-fold), but significantly more than 8- to 30-fold activation
achieved with previous designs.134,135,209 The antithrombin affinity was found to be
between 1 and 5 μM at pH 7.4. This is significantly higher than the affinities of all
previous designs (50 to 500 μM),171,212,214 though still less than most potent saccharidebased activators (50 to 100 nM).
Since the synthesized molecule was not originally present in the virtual library, this
molecule was docked using the same docking parameters. Modeling results for the
synthesized molecule shows that the GOLD score for 67A2L25 is 97.2, which is lower
than the scores for the hit molecules identified in the virtual library screening and the
binding modes are also divergent in triplicate docking experiments.
Several conclusions may be derived based on this single data point. 1) The
activation is not full (50-100 fold in comparison to 300-fold) for compound 67A2L25
probably because of the absence of optimal structural features, as predicted by GOLD
modeling; 2) the activation is much better than that realized with previous designs
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probably because of the slightly longer linker and/or 2′,5′-disulfation of the unicyclic ring;
3) the antithrombin affinity of 67A2L25 is found to be higher probably because of more
optimal features (slightly longer linker and/or 2,5-disulfation of unicyclic ring) than those
present in previous designs; and 4) the antithrombin affinity of 67A2L25 is not as great as
the most optimal saccharide activators because all of the features suggested by the docking
experiments have not been introduced. Overall, the antithrombin binding and activation
results obtained with 67A2L25 are consistent with the GOLD-based molecular modeling
results obtained and provide stronger impetus to synthesize and test the ‘high-affinity,
high-specificity’ molecules identified in this work.
In the second project, the specific and nonspecific interactions of heparin with
antithrombin and thrombin have been studied. Heparin exhibits its anticoagulant effect by
interacting with antithrombin and thrombin. Although the heparin binding sites in both
antithrombin and thrombin are lined with Arg and Lys amino acid residues, the
antithrombin-heparin interaction is specific, whereas the thrombin-heparin interaction is
considered to be nonspecific.
Our molecular modeling studies and the crystal structure analyses of antithrombin
and thrombin explain some of the factors that are responsible for specificity. Even though
one would expect long side chain amino acids such as Lys and Arg, which form the
heparin binding site (HBS) on the surface of antithrombin, to be highly surface exposed, it
was found that most of the critical amino acids in the HBS are instead ~60% buried. In
addition to the buried nature, they are also held in place by neighboring H-bonding
partners such Asp and Glu, which restricts the flexibility of the long side chains. In some
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cases, like Lys114, the hydrophobic environment keeps the long side chains close to the
protein rather than solvent exposed. Calculation of radii of gyration indicated that most of
the critical amino acids in HBS are spatially conserved. Analysis of the relative geometry
of the basic residues revealed an important feature wherein Lys114, Lys125 and Arg129
form a non-equilateral scalene triangle, which in principle would favor specific interaction
and require a complementary match from the ligand to be recognized. Since
pentasaccharide is a molecule with appropriately distributed charge functionalities that
meet the 3-D geometrical requirements of antithrombin HBS, the antithrombinpentasaccharide interaction becomes specific rather than simple nonspecific ionically
driven interactions between negatively charged ligand and positively charged protein
functional groups.
At the same time the heparin-thrombin interaction is presumed to be non-specific
even though the receptor-ligand interactions are very similar to those in antithrombin. In
contrast to antithrombin, we found that most of the basic long side chain amino acids in
thrombin exosite-II are more than ~60% surface exposed and are highly flexible. Also, the
important amino acids in the thrombin exosite-II are arranged in a highly symmetric
pattern which favors non-specific interaction due to multiple or degenerate binding mode.
However, calculation of radii of gyration showed that within this non-specific
favored thrombin exosite-II, Arg101, Arg165 and Arg233 are spatially conserved and form
a local asymmetric center. Using molecular docking experiments, we have designed novel
tetrasaccharide sequences to specifically recognize these amino acids. The newly-designed
‘best hit’ HS15a_3-O-SO3__HS15 sequence is 50% smaller in size and contains 62.5%
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fewer charged functionalities but has a nearly equal GOLD score in comparison to the hit
octasaccharide sequences that have 13 to 16 charges. This tetrasaccharide is not only
smaller in size with fewer charges but has better probability of making ‘specific’
interactions at thrombin exosite-II based on our repeated docking experiments.
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HS15a_3-O-SO3__HS15: GOLD Score 127
The design of novel ‘specific’ tetrasaccharide sequences challenges the existing
idea that the thrombin–heparin interaction is non-specific and leads to the possibility of
designing and synthesizing heparin-based specific thrombin exosite-II modulators. Since
we have already proved in our lab that it is possible to replace the saccharide backbone by
a non-saccharide skeleton in designing non-saccharide antithrombin activators, in principle
it is also possible to design non-saccharide mimics based on this novel sequence for
thrombin exosite-II.
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APPENDIX A
ABREVIATIONS
AT:

Antithrombin

HBS: Heparin binding site
PBS: Pentasaccharide Binding Site
EHBS: Extended Heparin Binding Site
GAG: Glycosaminoglycan
DEFGH (H5): Natural sequence-specific heparin pentasaccharide
LMWHs: Low Molecular Weight Heparins
ISOQ: Tetrahydroisoquinoline
QSAR: Quantitative Structure-Activity Relationship
QSPR: Quantitative Structure-Property Relationship
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